CHEBI ONTOLOGY - ANNOTATIONS
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/ . The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/ ). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term: bexarotene
Accession: CHEBI:50859
browse the term
Definition: A retinoid that has formula C24H28O2.
Synonyms: exact_synonym: 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl]benzoic acid
related_synonym: Formula=C24H28O2; InChI=1S/C24H28O2/c1-15-13-20-21(24(5,6)12-11-23(20,3)4)14-19(15)16(2)17-7-9-18(10-8-17)22(25)26/h7-10,13-14H,2,11-12H2,1,3-6H3,(H,25,26); InChIKey=NAVMQTYZDKMPEU-UHFFFAOYSA-N; SMILES=Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C; bexaroteno; bexarotenum; p-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid
xref: CAS:153559-49-0; DrugBank:DB00307; Drug_Central:361; KEGG:D03106
xref_mesh: MESH:C095105
xref: Patent:US5466861; Patent:WO9321146; Wikipedia:Bexarotene
G
A1bg
alpha-1-B glycoprotein
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of A1BG mRNA
CTD
PMID:17630414
NCBI chr 7:92,493,934...92,498,460
Ensembl chr 7:92,494,372...92,498,097
G
Abca1
ATP binding cassette subfamily A member 1
increases expression increases expression multiple interactions
ISO
bexarotene results in increased expression of ABCA1; bexarotene results in increased expression of ABCA1 mRNA bexarotene increases expression of abca1 protein in mouse hippocampus bexarotene increases expression of Abca1 protein in mouse cerebral cortex diazepinylbenzoic acid inhibits the reaction [bexarotene results in increased expression of ABCA1 mRNA] [bexarotene co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 protein
CTD RGD
PMID:21622945 PMID:25932594 PMID:25217640 PMID:26688581
RGD:21408550 , RGD:11056803
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
G
Abcb11
ATP binding cassette subfamily B member 11
increases expression
EXP
bexarotene results in increased expression of ABCB11 mRNA
CTD
PMID:16648578
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
G
Abcd3
ATP binding cassette subfamily D member 3
increases expression
EXP
bexarotene results in increased expression of ABCD3 mRNA
CTD
PMID:16648578 PMID:23292798
NCBI chr 2:209,852,087...209,905,763
Ensembl chr 2:209,852,087...209,906,020
G
Acaa1a
acetyl-CoA acyltransferase 1A
increases expression multiple interactions
EXP
bexarotene results in increased expression of ACAA1 mRNA; bexarotene results in increased expression of ACAA1A mRNA [Tamoxifen co-treated with bexarotene] results in increased expression of ACAA1 mRNA
CTD
PMID:16648578 PMID:17630414
NCBI chr 8:119,079,401...119,088,624
Ensembl chr 8:119,079,775...119,088,624
G
Acaca
acetyl-CoA carboxylase alpha
increases expression
EXP
bexarotene results in increased expression of ACACA mRNA
CTD
PMID:23292798
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
G
Acadm
acyl-CoA dehydrogenase medium chain
increases expression
EXP
bexarotene results in increased expression of ACADM mRNA
CTD
PMID:23292798
NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147
G
Acat1
acetyl-CoA acetyltransferase 1
increases expression multiple interactions
EXP
bexarotene results in increased expression of ACAT1 mRNA [Tamoxifen co-treated with bexarotene] results in increased expression of ACAT1 mRNA
CTD
PMID:16648578 PMID:17630414
NCBI chr 8:53,979,813...54,008,861
Ensembl chr 8:53,979,813...54,008,855
G
Ache
acetylcholinesterase
decreases expression
EXP
bexarotene results in decreased expression of ACHE mRNA
CTD
PMID:16648578
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
G
Acot1
acyl-CoA thioesterase 1
increases expression multiple interactions
EXP
Bexarotene results in increased expression of ACOT1 mRNA [Tamoxifen co-treated with Bexarotene] results in increased expression of ACOT1 mRNA
CTD
PMID:16648578 PMID:17630414
NCBI chr 6:103,636,173...103,644,167
Ensembl chr 6:103,636,041...103,644,163
G
Acot2
acyl-CoA thioesterase 2
increases expression
EXP
bexarotene results in increased expression of ACOT2 mRNA
CTD
PMID:16648578
NCBI chr 6:103,611,744...103,619,404
Ensembl chr 6:103,611,544...103,619,245
G
Acox1
acyl-CoA oxidase 1
increases expression
EXP
bexarotene results in increased expression of ACOX1 mRNA
CTD
PMID:16648578 PMID:23292798
NCBI chr10:101,406,197...101,431,242
Ensembl chr10:101,406,197...101,431,232
G
Acsl1
acyl-CoA synthetase long-chain family member 1
increases expression
EXP
bexarotene results in increased expression of ACSL1 mRNA
CTD
PMID:23292798
NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541
G
Acsl5
acyl-CoA synthetase long-chain family member 5
increases expression
EXP
bexarotene results in increased expression of ACSL5 mRNA
CTD
PMID:23292798
NCBI chr 1:254,289,513...254,336,608
Ensembl chr 1:254,292,521...254,336,607
G
Acsm3
acyl-CoA synthetase medium-chain family member 3
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of SAH mRNA
CTD
PMID:17630414
NCBI chr 1:174,133,260...174,159,966
Ensembl chr 1:174,133,288...174,160,184
G
Acta2
actin alpha 2, smooth muscle
increases expression
EXP
bexarotene results in increased expression of ACTA2 mRNA
CTD
PMID:16648578
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
G
Actc1
actin, alpha, cardiac muscle 1
increases expression
EXP
bexarotene results in increased expression of ACTC1 mRNA
CTD
PMID:16648578
NCBI chr 3:100,811,987...100,817,523
Ensembl chr 3:100,811,987...100,817,523
G
Actg1
actin, gamma 1
increases expression
EXP
bexarotene results in increased expression of ACTG1 mRNA
CTD
PMID:16648578
NCBI chr10:105,619,738...105,622,587
Ensembl chr10:105,619,737...105,624,232
G
Acvr2b
activin A receptor type 2B
increases expression
EXP
bexarotene results in increased expression of ACVR2B mRNA
CTD
PMID:16648578
NCBI chr 8:119,138,901...119,178,477
Ensembl chr 8:119,138,812...119,170,458
G
Adcy6
adenylate cyclase 6
decreases expression
EXP
bexarotene results in decreased expression of ADCY6 mRNA
CTD
PMID:16648578
NCBI chr 7:129,742,827...129,763,922
Ensembl chr 7:129,742,838...129,763,754
G
Add3
adducin 3
increases expression
ISO
bexarotene results in increased expression of ADD3 mRNA
CTD
PMID:17178900
NCBI chr 1:252,147,341...252,255,126
Ensembl chr 1:252,147,386...252,255,124
G
Adh4
alcohol dehydrogenase 4 (class II), pi polypeptide
increases expression
EXP
bexarotene results in increased expression of ADH4 mRNA
CTD
PMID:17630414
NCBI chr 2:226,948,717...226,966,747
Ensembl chr 2:226,947,466...226,987,591
G
Adig
adipogenin
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of ADIG mRNA
CTD
PMID:17630414
NCBI chr 3:147,155,021...147,160,413
G
Adra1b
adrenoceptor alpha 1B
decreases expression
EXP
bexarotene results in decreased expression of ADRA1B mRNA
CTD
PMID:16648578
NCBI chr10:28,255,025...28,373,418
Ensembl chr10:28,255,025...28,312,919
G
Adrb2
adrenoceptor beta 2
decreases expression
ISO
bexarotene results in decreased expression of ADRB2 mRNA
CTD
PMID:17178900
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
G
Agxt
alanine--glyoxylate and serine--pyruvate aminotransferase
increases expression
EXP
bexarotene results in increased expression of AGXT mRNA
CTD
PMID:16648578
NCBI chr 9:93,675,384...93,685,337
Ensembl chr 9:93,675,384...93,685,336
G
Ahsg
alpha-2-HS-glycoprotein
decreases expression
EXP
bexarotene results in decreased expression of AHSG mRNA
CTD
PMID:16648578
NCBI chr11:78,117,903...78,145,956
Ensembl chr11:78,117,918...78,145,999
G
Akap12
A-kinase anchoring protein 12
increases expression
EXP
bexarotene results in increased expression of AKAP12 mRNA
CTD
PMID:16648578
NCBI chr 1:40,730,123...40,819,863
Ensembl chr 1:40,730,123...40,819,886
G
Akr1c1
aldo-keto reductase family 1, member C1
increases expression
ISO
Bexarotene results in increased expression of AKR1C1 mRNA
CTD
PMID:17178900
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
G
Akr1c3
aldo-keto reductase family 1, member C3
increases expression
ISO
bexarotene results in increased expression of AKR1C3 mRNA
CTD
PMID:17178900
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
G
Aldh3a2
aldehyde dehydrogenase 3 family, member A2
decreases expression
EXP
bexarotene results in decreased expression of ALDH3A2 mRNA
CTD
PMID:16648578
NCBI chr10:45,928,313...45,949,366
Ensembl chr10:45,908,524...45,949,281
G
Aldoa
aldolase, fructose-bisphosphate A
increases expression
EXP
Bexarotene results in increased expression of ALDOA mRNA
CTD
PMID:16648578
NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182
G
Aldob
aldolase, fructose-bisphosphate B
decreases expression
EXP
bexarotene results in decreased expression of ALDOB mRNA
CTD
PMID:16648578
NCBI chr 5:63,889,045...63,902,086
Ensembl chr 5:63,889,046...63,902,116
G
Aldoc
aldolase, fructose-bisphosphate C
increases expression
EXP
bexarotene results in increased expression of ALDOC mRNA
CTD
PMID:16648578
NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066
G
Alpl
alkaline phosphatase, biomineralization associated
increases expression
EXP
bexarotene results in increased expression of ALPL mRNA
CTD
PMID:16648578
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
G
Amotl2
angiomotin like 2
decreases expression
ISO
bexarotene results in decreased expression of AMOTL2 mRNA
CTD
PMID:17178900
NCBI chr 8:103,303,368...103,319,161
Ensembl chr 8:103,302,992...103,318,910
G
Angptl4
angiopoietin-like 4
increases expression
ISO
bexarotene results in increased expression of ANGPTL4 mRNA
CTD
PMID:21622945
NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519
G
Ank3
ankyrin 3
decreases expression
EXP
bexarotene results in decreased expression of ANK3 mRNA
CTD
PMID:16648578
NCBI chr20:18,602,267...19,225,831
Ensembl chr20:18,602,786...19,086,300
G
Anxa3
annexin A3
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of ANXA3 mRNA
CTD
PMID:17630414
NCBI chr14:12,727,708...12,781,717
Ensembl chr14:12,719,795...12,781,617
G
Aplp2
amyloid beta precursor like protein 2
increases expression
EXP
bexarotene results in increased expression of APLP2 mRNA
CTD
PMID:16648578
NCBI chr 8:29,599,230...29,662,311
Ensembl chr 8:29,599,230...29,661,855
G
Apoa2
apolipoprotein A2
multiple interactions increases expression decreases expression
ISO EXP
RXRA promotes the reaction [bexarotene results in increased expression of APOA2 mRNA] bexarotene results in decreased expression of APOA2 mRNA
CTD
PMID:8668150 PMID:16648578
NCBI chr13:83,644,460...83,646,358
Ensembl chr13:83,644,470...83,646,355
G
Apob
apolipoprotein B
decreases expression
EXP
bexarotene results in decreased expression of APOB mRNA
CTD
PMID:16648578
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
G
Apoc1
apolipoprotein C1
decreases expression
EXP
bexarotene results in decreased expression of APOC1 mRNA
CTD
PMID:16648578
NCBI chr 1:79,347,057...79,350,340
Ensembl chr 1:79,346,136...79,350,375
G
Apoc3
apolipoprotein C3
decreases expression
EXP
bexarotene results in decreased expression of APOC3 mRNA
CTD
PMID:16648578
NCBI chr 8:46,531,478...46,533,658
Ensembl chr 8:46,531,478...46,533,583
G
Apod
apolipoprotein D
increases expression
ISO
bexarotene results in increased expression of APOD mRNA
CTD
PMID:17849452
NCBI chr11:69,431,261...69,452,306
Ensembl chr11:69,431,260...69,452,305
G
App
amyloid beta precursor protein
increases expression
EXP
bexarotene results in increased expression of APP mRNA
CTD
PMID:16648578
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
G
Aqp7
aquaporin 7
multiple interactions decreases expression
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of AQP7 mRNA bexarotene results in decreased expression of AQP7 mRNA
CTD
PMID:16648578 PMID:17630414
NCBI chr 5:56,171,649...56,186,642
Ensembl chr 5:56,172,519...56,186,642
G
Ar
androgen receptor
multiple interactions increases expression
ISO EXP
bexarotene binds to and results in decreased activity of AR protein bexarotene results in increased expression of AR mRNA
CTD
PMID:16648578 PMID:25752796
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
G
Arf1
ADP-ribosylation factor 1
increases expression
EXP
bexarotene results in increased expression of ARF1 mRNA
CTD
PMID:16648578
NCBI chr10:43,997,983...44,014,543
Ensembl chr10:43,997,986...44,014,434
G
Arg1
arginase 1
decreases expression
EXP
bexarotene results in decreased expression of ARG1 mRNA
CTD
PMID:16648578
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
G
Arl6ip5
ADP-ribosylation factor like GTPase 6 interacting protein 5
increases expression
ISO
bexarotene results in increased expression of ARL6IP5 mRNA
CTD
PMID:17178900
NCBI chr 4:129,810,650...129,838,628
Ensembl chr 4:129,810,645...129,838,608
G
Arpc1b
actin related protein 2/3 complex, subunit 1B
increases expression
EXP
bexarotene results in increased expression of ARPC1B mRNA
CTD
PMID:16648578
NCBI chr12:9,482,176...9,495,772
Ensembl chr12:9,480,831...9,495,747
G
Ascl1
achaete-scute family bHLH transcription factor 1
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of ASCL1 mRNA
CTD
PMID:17630414
NCBI chr 7:21,904,153...21,906,003
Ensembl chr 7:21,903,126...21,905,993
G
Asgr1
asialoglycoprotein receptor 1
increases expression
EXP
bexarotene results in increased expression of ASGR1 mRNA
CTD
PMID:16648578
NCBI chr10:54,775,727...54,779,642
Ensembl chr10:54,776,024...54,779,631
G
Asns
asparagine synthetase (glutamine-hydrolyzing)
decreases expression
ISO
bexarotene results in decreased expression of ASNS mRNA
CTD
PMID:17178900
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
G
Atm
ATM serine/threonine kinase
increases activity
ISO
bexarotene results in increased activity of ATM protein
CTD
PMID:19067706
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
G
Atp1a1
ATPase Na+/K+ transporting subunit alpha 1
increases expression
EXP
bexarotene results in increased expression of ATP1A1 mRNA
CTD
PMID:16648578
NCBI chr 2:189,020,722...189,048,826
Ensembl chr 2:189,020,722...189,048,837
G
Atp1b1
ATPase Na+/K+ transporting subunit beta 1
decreases expression
EXP
bexarotene results in decreased expression of ATP1B1 mRNA
CTD
PMID:16648578
NCBI chr13:76,786,580...76,807,096
Ensembl chr13:76,786,578...76,807,459
G
Atp4a
ATPase H+/K+ transporting subunit alpha
increases expression
EXP
bexarotene results in increased expression of ATP4A mRNA
CTD
PMID:16648578
NCBI chr 1:85,961,607...85,974,972
Ensembl chr 1:85,961,708...85,974,844
G
Atp5f1d
ATP synthase F1 subunit delta
increases expression
EXP
bexarotene results in increased expression of ATP5F1D mRNA
CTD
PMID:16648578
NCBI chr 7:9,560,604...9,565,919
Ensembl chr 7:9,560,608...9,565,929
G
Atp6v0c
ATPase H+ transporting V0 subunit C
increases expression
EXP
bexarotene results in increased expression of ATP6V0C mRNA
CTD
PMID:16648578
NCBI chr10:13,196,204...13,202,580
Ensembl chr10:13,196,204...13,201,500
G
Bax
BCL2 associated X, apoptosis regulator
multiple interactions
ISO
bexarotene results in increased expression of and results in increased activity of BAX protein
CTD
PMID:19067706
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
G
Bbs2
Bardet-Biedl syndrome 2
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of BBS2 mRNA
CTD
PMID:17630414
NCBI chr19:10,909,653...10,944,998
Ensembl chr19:10,909,619...10,944,993
G
Bglap
bone gamma-carboxyglutamate protein
multiple interactions
ISO
bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]
CTD
PMID:25932594
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
G
Bhlhe41
basic helix-loop-helix family, member e41
decreases expression
EXP
bexarotene results in decreased expression of BHLHE41 mRNA
CTD
PMID:16648578
NCBI chr 4:178,833,085...178,838,685
Ensembl chr 4:178,834,271...178,838,468
G
Birc5
baculoviral IAP repeat-containing 5
decreases expression
ISO
bexarotene results in decreased expression of BIRC5 mRNA bexarotene results in decreased expression of BIRC5 protein
CTD
PMID:17849452 PMID:19067706
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
G
Bmp2
bone morphogenetic protein 2
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of BMP2 mRNA
CTD
PMID:17630414
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
G
Bnip2
BCL2 interacting protein 2
decreases expression
ISO
bexarotene results in decreased expression of BNIP2 mRNA
CTD
PMID:17178900
NCBI chr 8:70,640,436...70,661,782
Ensembl chr 8:70,640,445...70,675,590
G
Btg2
BTG anti-proliferation factor 2
decreases expression
EXP
bexarotene results in decreased expression of BTG2 mRNA
CTD
PMID:16648578
NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
G
C1qb
complement C1q B chain
multiple interactions increases expression
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of C1QB mRNA bexarotene results in increased expression of C1QB mRNA
CTD
PMID:16648578 PMID:17630414
NCBI chr 5:149,118,843...149,124,394
Ensembl chr 5:149,118,846...149,124,407
G
C3
complement C3
decreases expression
EXP
bexarotene results in decreased expression of C3 mRNA
CTD
PMID:16648578
NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429
G
C4bpa
complement component 4 binding protein, alpha
decreases expression
EXP
bexarotene results in decreased expression of C4BPA mRNA
CTD
PMID:16648578
NCBI chr13:42,075,715...42,111,205
Ensembl chr13:42,075,717...42,111,205
G
Cacna2d3
calcium voltage-gated channel auxiliary subunit alpha2delta 3
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of CACNA2D3 mRNA
CTD
PMID:17630414
NCBI chr16:4,098,439...4,912,498
Ensembl chr16:4,098,445...4,912,351
G
Calr
calreticulin
increases expression
EXP
bexarotene results in increased expression of CALR mRNA
CTD
PMID:16648578
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
G
Camk2g
calcium/calmodulin-dependent protein kinase II gamma
increases expression
EXP
bexarotene results in increased expression of CAMK2G mRNA
CTD
PMID:16648578
NCBI chr15:3,504,017...3,563,050
Ensembl chr15:3,504,085...3,563,050
G
Canx
calnexin
increases expression
EXP
bexarotene results in increased expression of CANX mRNA
CTD
PMID:16648578
NCBI chr10:34,623,865...34,656,866
Ensembl chr10:34,625,191...34,656,821
G
Casp3
caspase 3
decreases expression
ISO
bexarotene results in decreased expression of CASP3 mRNA
CTD
PMID:17849452
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
G
Casp6
caspase 6
decreases expression
EXP
bexarotene results in decreased expression of CASP6 mRNA
CTD
PMID:16648578
NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502
G
Ccl11
C-C motif chemokine ligand 11
decreases expression
EXP
bexarotene results in decreased expression of CCL11 mRNA
CTD
PMID:16648578
NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926
G
Ccn1
cellular communication network factor 1
decreases expression
ISO
Bexarotene results in decreased expression of CCN1 mRNA
CTD
PMID:17178900
NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
G
Ccnb1
cyclin B1
decreases expression
ISO
bexarotene results in decreased expression of CCNB1 protein
CTD
PMID:19067706
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
G
Ccnb2
cyclin B2
decreases expression
ISO
bexarotene results in decreased expression of CCNB2 mRNA
CTD
PMID:17849452
NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874
G
Ccnd1
cyclin D1
increases expression decreases expression
EXP ISO
bexarotene results in increased expression of CCND1 mRNA bexarotene results in decreased expression of CCND1 mRNA
CTD
PMID:16648578 PMID:17178900
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
G
Ccne1
cyclin E1
decreases expression
ISO
bexarotene results in decreased expression of CCNE1 mRNA
CTD
PMID:17849452
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
G
Cd14
CD14 molecule
increases expression
EXP
bexarotene results in increased expression of CD14 mRNA
CTD
PMID:16648578
NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261
G
Cd36
CD36 molecule
increases expression
EXP
bexarotene results in increased expression of CD36 mRNA
CTD
PMID:16648578 PMID:23292798
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
G
Cd37
CD37 molecule
increases expression
EXP
bexarotene results in increased expression of CD37 mRNA
CTD
PMID:16648578
NCBI chr 1:95,719,171...95,724,662
Ensembl chr 1:95,719,190...95,724,648
G
Cd48
Cd48 molecule
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of CD48 mRNA
CTD
PMID:17630414
NCBI chr13:84,184,884...84,209,144
Ensembl chr13:84,185,532...84,209,142
G
Cd5l
Cd5 molecule-like
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of CD5L mRNA
CTD
PMID:17630414
NCBI chr 2:172,791,007...172,802,018
Ensembl chr 2:172,790,934...172,829,753
G
Cd68
Cd68 molecule
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of CD68 mRNA
CTD
PMID:17630414
NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
G
Cd74
CD74 molecule
increases expression
EXP
bexarotene results in increased expression of CD74 mRNA
CTD
PMID:16648578
NCBI chr18:54,256,757...54,266,003
Ensembl chr18:54,256,778...54,266,003
G
Cdc37
cell division cycle 37, HSP90 cochaperone
increases expression
EXP
bexarotene results in increased expression of CDC37 mRNA
CTD
PMID:16648578
NCBI chr 8:19,677,400...19,690,761
Ensembl chr 8:19,671,938...19,690,809
G
Cdk1
cyclin-dependent kinase 1
decreases expression
ISO
bexarotene results in decreased expression of CDK1 protein
CTD
PMID:19067706
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
G
Cdkn1a
cyclin-dependent kinase inhibitor 1A
increases expression
ISO
bexarotene results in increased expression of CDKN1A protein
CTD
PMID:19067706
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
G
Cdo1
cysteine dioxygenase type 1
decreases expression
EXP
bexarotene results in decreased expression of CDO1 mRNA
CTD
PMID:16648578
NCBI chr18:39,432,473...39,447,253
Ensembl chr18:39,432,474...39,447,296
G
Cebpg
CCAAT/enhancer binding protein gamma
decreases expression
ISO
bexarotene results in decreased expression of CEBPG mRNA
CTD
PMID:17178900
NCBI chr 1:87,683,060...87,692,772
Ensembl chr 1:87,684,019...87,694,569
G
Ces2h
carboxylesterase 2H
increases expression multiple interactions
EXP
bexarotene results in increased expression of CES2 mRNA [Tamoxifen co-treated with bexarotene] results in increased expression of CES2 mRNA
CTD
PMID:16648578 PMID:17630414
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
G
Cfd
complement factor D
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of CFD mRNA
CTD
PMID:17630414
NCBI chr 7:9,813,148...9,814,871
Ensembl chr 7:9,813,150...9,815,053
G
Chrna2
cholinergic receptor nicotinic alpha 2 subunit
increases expression
EXP
bexarotene results in increased expression of CHRNA2 mRNA
CTD
PMID:16648578 PMID:17630414
NCBI chr15:40,342,317...40,358,601
Ensembl chr15:40,342,317...40,358,601
G
Ciao1
cytosolic iron-sulfur assembly component 1
decreases expression
EXP
bexarotene results in decreased expression of CIAO1 mRNA
CTD
PMID:16648578
NCBI chr 3:114,458,671...114,465,928
Ensembl chr 3:114,458,655...114,467,009
G
Ckb
creatine kinase B
increases expression
EXP
bexarotene results in increased expression of CKB mRNA
CTD
PMID:16648578
NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315
G
Cldn3
claudin 3
increases expression
EXP
bexarotene results in increased expression of CLDN3 mRNA
CTD
PMID:16648578
NCBI chr12:21,708,538...21,710,010
Ensembl chr12:21,708,398...21,711,001
G
Cldn7
claudin 7
increases expression
EXP
bexarotene results in increased expression of CLDN7 mRNA
CTD
PMID:16648578
NCBI chr10:54,689,684...54,692,177
Ensembl chr10:54,689,987...54,692,171
G
Col12a1
collagen type XII alpha 1 chain
decreases expression
EXP
bexarotene results in decreased expression of COL12A1 mRNA
CTD
PMID:16648578
NCBI chr 8:80,547,592...80,665,665
Ensembl chr 8:80,547,593...80,665,686
G
Colq
collagen like tail subunit of asymmetric acetylcholinesterase
increases expression
EXP
bexarotene results in increased expression of COLQ mRNA
CTD
PMID:16648578
NCBI chr16:6,731,850...6,824,973
Ensembl chr16:6,731,858...6,787,107
G
Comt
catechol-O-methyltransferase
decreases expression increases expression
EXP
bexarotene results in decreased expression of COMT mRNA bexarotene results in increased expression of COMT mRNA
CTD
PMID:16648578
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
G
Coro1b
coronin 1B
increases expression
EXP
bexarotene results in increased expression of CORO1B mRNA
CTD
PMID:16648578
NCBI chr 1:201,442,977...201,448,416
Ensembl chr 1:201,443,014...201,448,416
G
Cpa1
carboxypeptidase A1
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of CPA1 mRNA
CTD
PMID:17630414
NCBI chr 4:59,257,417...59,263,544
Ensembl chr 4:59,257,417...59,263,544
G
Cps1
carbamoyl-phosphate synthase 1
decreases expression
EXP
bexarotene results in decreased expression of CPS1 mRNA
CTD
PMID:16648578
NCBI chr 9:68,614,153...68,737,037
Ensembl chr 9:68,614,153...68,737,033
G
Cpt1b
carnitine palmitoyltransferase 1B
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of CPT1B mRNA
CTD
PMID:17630414
NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404
G
Cpt2
carnitine palmitoyltransferase 2
increases expression
EXP
bexarotene results in increased expression of CPT2 mRNA
CTD
PMID:16648578
NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095
G
Crot
carnitine O-octanoyltransferase
increases expression
EXP
bexarotene results in increased expression of CROT mRNA
CTD
PMID:16648578
NCBI chr 4:25,068,270...25,133,111
Ensembl chr 4:25,080,587...25,133,109
G
Csf1r
colony stimulating factor 1 receptor
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of CSF1R mRNA
CTD
PMID:17630414
NCBI chr18:54,546,673...54,590,418
Ensembl chr18:54,546,659...54,590,415
G
Cspg5
chondroitin sulfate proteoglycan 5
increases expression
EXP
bexarotene results in increased expression of CSPG5 mRNA
CTD
PMID:16648578
NCBI chr 8:110,220,653...110,234,750
Ensembl chr 8:110,220,653...110,234,758
G
Csrp2
cysteine and glycine-rich protein 2
decreases expression
EXP
bexarotene results in decreased expression of CSRP2 mRNA
CTD
PMID:16648578
NCBI chr 7:46,349,109...46,367,743
Ensembl chr 7:46,348,686...46,367,745
G
Cth
cystathionine gamma-lyase
decreases expression
ISO
bexarotene results in decreased expression of CTH mRNA
CTD
PMID:17178900
NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234
G
Ctrc
chymotrypsin C
increases expression
EXP
bexarotene results in increased expression of CTRC mRNA
CTD
PMID:16648578
NCBI chr 5:154,147,314...154,156,540
Ensembl chr 5:154,147,316...154,156,528
G
Ctsh
cathepsin H
increases expression
ISO
bexarotene results in increased expression of CTSH mRNA
CTD
PMID:17178900
NCBI chr 8:90,608,941...90,627,824
Ensembl chr 8:90,608,941...90,627,824
G
Cxcl1
C-X-C motif chemokine ligand 1
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of CXCL1 mRNA
CTD
PMID:17630414
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
G
Cxcl14
C-X-C motif chemokine ligand 14
decreases expression
EXP
bexarotene results in decreased expression of CXCL14 mRNA
CTD
PMID:16648578
NCBI chr17:8,317,933...8,325,956
Ensembl chr17:8,317,933...8,324,839
G
Cxcl3
C-X-C motif chemokine ligand 3
decreases expression
EXP
bexarotene results in decreased expression of CXCL3 mRNA
CTD
PMID:16648578
NCBI chr14:17,270,146...17,289,458
Ensembl chr14:17,270,146...17,289,511
G
Cyb5a
cytochrome b5 type A
decreases expression
EXP
bexarotene results in decreased expression of CYB5A mRNA
CTD
PMID:16648578
NCBI chr18:78,213,067...78,245,677
Ensembl chr18:78,202,342...78,258,535 Ensembl chr18:78,202,342...78,258,535
G
Cycs
cytochrome c, somatic
decreases expression
ISO
bexarotene results in decreased expression of CYCS mRNA
CTD
PMID:17178900
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
G
Cyp17a1
cytochrome P450, family 17, subfamily a, polypeptide 1
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of CYP17A1 mRNA
CTD
PMID:17630414
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
G
Cyp1a2
cytochrome P450, family 1, subfamily a, polypeptide 2
decreases expression
EXP
bexarotene results in decreased expression of CYP1A2 mRNA
CTD
PMID:16648578
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
G
Cyp1b1
cytochrome P450, family 1, subfamily b, polypeptide 1
increases expression
EXP
bexarotene results in increased expression of CYP1B1 mRNA
CTD
PMID:16648578
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
G
Cyp26a1
cytochrome P450, family 26, subfamily a, polypeptide 1
increases expression multiple interactions
ISO EXP
bexarotene results in increased expression of CYP26A1 mRNA [bexarotene co-treated with Tamoxifen] results in increased expression of CYP26A1 mRNA
CTD
PMID:17178900 PMID:17630414
NCBI chr 1:235,471,368...235,475,204
Ensembl chr 1:235,471,298...235,475,204
G
Cyp26b1
cytochrome P450, family 26, subfamily b, polypeptide 1
increases expression
ISO
bexarotene results in increased expression of CYP26B1 mRNA
CTD
PMID:17849452
NCBI chr 4:117,041,808...117,058,628
Ensembl chr 4:117,041,808...117,058,628
G
Cyp27a1
cytochrome P450, family 27, subfamily a, polypeptide 1
increases expression
EXP
bexarotene results in increased expression of CYP27A1 mRNA
CTD
PMID:16648578
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
G
Cyp2a1
cytochrome P450, family 2, subfamily a, polypeptide 1
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of CYP2A1 mRNA
CTD
PMID:17630414
NCBI chr 1:82,231,611...82,244,887
Ensembl chr 1:82,231,611...82,244,887
G
Cyp2a2
cytochrome P450, family 2, subfamily a, polypeptide 2
decreases expression
EXP
bexarotene results in decreased expression of CYP2A2 mRNA
CTD
PMID:16648578
NCBI chr 1:82,263,833...82,289,487
Ensembl chr 1:82,263,833...82,289,487
G
Cyp2b1
cytochrome P450, family 2, subfamily b, polypeptide 1
increases expression
EXP
bexarotene results in increased expression of CYP2B1 mRNA
CTD
PMID:23292798
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
G
Cyp2b15
cytochrome P450, family 2, subfamily b, polypeptide 15
increases expression
EXP
bexarotene results in increased expression of CYP2B15 mRNA
CTD
PMID:16648578
NCBI chr 1:82,094,188...82,106,492
Ensembl chr 1:82,094,180...82,106,492
G
Cyp2b2
cytochrome P450, family 2, subfamily b, polypeptide 2
increases expression
EXP
bexarotene results in increased expression of CYP2B2 mRNA
CTD
PMID:16648578
NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566
G
Cyp2b3
cytochrome P450, family 2, subfamily b, polypeptide 3
increases expression multiple interactions
ISO
Bexarotene results in increased expression of CYP2B6 mRNA RXRA protein affects the reaction [Bexarotene results in increased expression of CYP2B6 mRNA]
CTD
PMID:31312845
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
G
Cyp2c12
cytochrome P450, family 2, subfamily c, polypeptide 12
decreases expression
EXP
bexarotene results in decreased expression of CYP2C12 mRNA
CTD
PMID:16648578
NCBI chr 1:238,699,859...238,757,011
Ensembl chr 1:238,699,854...238,757,019
G
Cyp2c7
cytochrome P450, family 2, subfamily c, polypeptide 7
decreases expression
EXP
bexarotene results in decreased expression of CYP2C7 mRNA
CTD
PMID:16648578
NCBI chr 1:237,332,641...237,388,714
Ensembl chr 1:237,332,659...237,388,709
G
Cyp2d3
cytochrome P450, family 2, subfamily d, polypeptide 3
increases expression
EXP
bexarotene results in increased expression of CYP2D3 mRNA
CTD
PMID:16648578
NCBI chr 7:113,917,711...113,922,068
Ensembl chr 7:113,908,947...113,922,084
G
Cyp2t1
cytochrome P450, family 2, subfamily t, polypeptide 1
decreases expression multiple interactions
EXP
bexarotene results in decreased expression of CYP2T1 mRNA [Tamoxifen co-treated with bexarotene] results in decreased expression of CYP2T1 mRNA
CTD
PMID:17630414
NCBI chr 1:82,446,321...82,451,564
Ensembl chr 1:82,446,921...82,451,563
G
Cyp3a18
cytochrome P450, family 3, subfamily a, polypeptide 18
decreases expression
EXP
bexarotene results in decreased expression of CYP3A18 mRNA
CTD
PMID:16648578
NCBI chr12:8,880,528...8,930,382
Ensembl chr12:8,880,528...8,930,381
G
Cyp3a23-3a1
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1
decreases expression increases expression
EXP
Bexarotene results in decreased expression of CYP3A23-3A1 mRNA Bexarotene results in increased expression of CYP3A23-3A1 mRNA
CTD
PMID:16648578 PMID:23292798
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
G
Cyp4a1
cytochrome P450, family 4, subfamily a, polypeptide 1
increases expression
EXP
bexarotene results in increased expression of CYP4A22 mRNA
CTD
PMID:16648578
NCBI chr 5:129,123,323...129,137,464
Ensembl chr 5:129,123,336...129,137,464
G
Cyp4f1
cytochrome P450, family 4, subfamily f, polypeptide 1
decreases expression
EXP
bexarotene results in decreased expression of CYP4F1 mRNA
CTD
PMID:16648578
NCBI chr 7:12,010,850...12,022,497
Ensembl chr 7:12,010,852...12,022,046
G
Cyp8b1
cytochrome P450 family 8 subfamily B member 1
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of CYP8B1 mRNA
CTD
PMID:17630414
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
G
Dab2
DAB adaptor protein 2
decreases expression
EXP
Bexarotene results in decreased expression of DAB2 mRNA
CTD
PMID:16648578
NCBI chr 2:55,514,692...55,567,476
Ensembl chr 2:55,514,700...55,567,476
G
Dact2
dishevelled-binding antagonist of beta-catenin 2
increases expression
EXP
bexarotene results in increased expression of DACT2 mRNA
CTD
PMID:17630414
NCBI chr 1:55,181,023...55,191,026
Ensembl chr 1:55,181,024...55,191,096
G
Dapk3
death-associated protein kinase 3
decreases expression
EXP
bexarotene results in decreased expression of DAPK3 mRNA
CTD
PMID:16648578
NCBI chr 7:8,524,182...8,532,552
Ensembl chr 7:8,524,183...8,532,558
G
Dbp
D-box binding PAR bZIP transcription factor
decreases expression
EXP
bexarotene results in decreased expression of DBP mRNA
CTD
PMID:16648578
NCBI chr 1:96,175,796...96,180,745
Ensembl chr 1:96,175,440...96,180,745
G
Ddit3
DNA-damage inducible transcript 3
decreases expression
EXP
bexarotene results in decreased expression of DDIT3 mRNA
CTD
PMID:16648578
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
G
Ddit4
DNA-damage-inducible transcript 4
increases expression
ISO
bexarotene results in increased expression of DDIT4 mRNA
CTD
PMID:17178900
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
G
Decr2
2,4-dienoyl-CoA reductase 2
increases expression
EXP
bexarotene results in increased expression of DECR2 mRNA
CTD
PMID:16648578
NCBI chr10:15,104,907...15,113,281
Ensembl chr10:15,002,926...15,118,479
G
Depp1
DEPP1, autophagy regulator
increases expression
ISO
bexarotene results in increased expression of DEPP1 mRNA
CTD
PMID:17178900
NCBI chr 4:149,910,794...149,913,013
Ensembl chr 4:149,910,779...149,914,542
G
Dhcr7
7-dehydrocholesterol reductase
increases expression
EXP
bexarotene results in increased expression of DHCR7 mRNA
CTD
PMID:16648578
NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055
G
Dhrs3
dehydrogenase/reductase 3
increases expression
ISO
bexarotene results in increased expression of DHRS3 mRNA
CTD
PMID:17178900
NCBI chr 5:156,747,939...156,782,420
Ensembl chr 5:156,747,962...156,782,417
G
Dkk1
dickkopf WNT signaling pathway inhibitor 1
increases expression
ISO
bexarotene results in increased expression of DKK1 mRNA
CTD
PMID:17178900
NCBI chr 1:228,381,521...228,385,202
Ensembl chr 1:228,381,521...228,385,202
G
Dlat
dihydrolipoamide S-acetyltransferase
increases expression
EXP
bexarotene results in increased expression of DLAT mRNA
CTD
PMID:16648578
NCBI chr 8:50,979,151...51,004,435
Ensembl chr 8:50,978,051...51,004,479
G
Dmp1
dentin matrix acidic phosphoprotein 1
multiple interactions
ISO
bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA]
CTD
PMID:25932594
NCBI chr14:5,528,441...5,542,078
Ensembl chr14:5,528,431...5,539,323
G
Dnaja1
DnaJ heat shock protein family (Hsp40) member A1
decreases expression
EXP
bexarotene results in decreased expression of DNAJA1 mRNA
CTD
PMID:16648578
NCBI chr 5:55,842,414...55,853,326
Ensembl chr 5:55,842,426...55,853,967
G
Dnmt3a
DNA methyltransferase 3 alpha
decreases expression
ISO
bexarotene results in decreased expression of DNMT3A mRNA
CTD
PMID:17849452
NCBI chr 6:26,791,517...26,902,161
Ensembl chr 6:26,822,609...26,896,687
G
Dusp1
dual specificity phosphatase 1
decreases expression
ISO EXP
bexarotene results in decreased expression of DUSP1 mRNA
CTD
PMID:16648578 PMID:17178900
NCBI chr10:16,680,489...16,683,276
G
Dusp5
dual specificity phosphatase 5
decreases expression
ISO
bexarotene results in decreased expression of DUSP5 mRNA
CTD
PMID:17178900
NCBI chr 1:252,538,408...252,555,320
Ensembl chr 1:252,538,449...252,551,818
G
Dync1i2
dynein cytoplasmic 1 intermediate chain 2
decreases expression
EXP
bexarotene results in decreased expression of DYNC1I2 mRNA
CTD
PMID:16648578
NCBI chr 3:56,033,882...56,085,080
Ensembl chr 3:56,033,917...56,085,080
G
Ech1
enoyl-CoA hydratase 1
increases expression
EXP
bexarotene results in increased expression of ECH1 mRNA
CTD
PMID:23292798
NCBI chr 1:84,114,494...84,120,788
Ensembl chr 1:84,112,751...84,120,795
G
Echdc1
ethylmalonyl-CoA decarboxylase 1
increases expression
EXP
bexarotene results in increased expression of ECHDC1 mRNA
CTD
PMID:23292798
NCBI chr 1:28,476,354...28,507,173
Ensembl chr 1:28,476,200...28,507,319
G
Eci1
enoyl-CoA delta isomerase 1
increases expression
EXP
bexarotene results in increased expression of ECI1 mRNA
CTD
PMID:16648578
NCBI chr10:13,456,715...13,470,061
Ensembl chr10:13,456,563...13,470,061
G
Ednrb
endothelin receptor type B
increases expression
EXP
bexarotene results in increased expression of EDNRB mRNA
CTD
PMID:16648578
NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
G
Egf
epidermal growth factor
increases expression
EXP
bexarotene results in increased expression of EGF mRNA
CTD
PMID:16648578
NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
G
Egr1
early growth response 1
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of EGR1 mRNA
CTD
PMID:17630414
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
G
Egr3
early growth response 3
decreases expression
ISO
bexarotene results in decreased expression of EGR3 mRNA
CTD
PMID:17178900
NCBI chr15:45,150,335...45,156,052
Ensembl chr15:45,150,567...45,154,627
G
Ehhadh
enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase
multiple interactions increases expression
EXP
[Tamoxifen co-treated with bexarotene] results in increased expression of EHHADH mRNA bexarotene results in increased expression of EHHADH mRNA
CTD
PMID:16648578 PMID:17630414
NCBI chr11:79,241,927...79,275,173
Ensembl chr11:79,241,938...79,275,188
G
Eif1
eukaryotic translation initiation factor 1
decreases expression
ISO
bexarotene results in decreased expression of EIF1 mRNA
CTD
PMID:17178900
NCBI chr10:85,246,751...85,248,842
Ensembl chr10:85,246,764...85,427,327
G
Eif3c
eukaryotic translation initiation factor 3, subunit C
decreases expression
EXP
bexarotene results in decreased expression of EIF3C mRNA
CTD
PMID:17630414
NCBI chr 1:181,134,604...181,152,489
Ensembl chr 1:181,134,604...181,152,493
G
Elovl6
ELOVL fatty acid elongase 6
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of ELOVL6 mRNA
CTD
PMID:17630414
NCBI chr 2:218,063,682...218,174,767
Ensembl chr 2:218,063,804...218,171,186
G
Eno1
enolase 1
increases expression
EXP
bexarotene results in increased expression of ENO1 mRNA
CTD
PMID:16648578
NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336
G
Enpp2
ectonucleotide pyrophosphatase/phosphodiesterase 2
decreases expression
EXP
bexarotene results in decreased expression of ENPP2 mRNA
CTD
PMID:16648578
NCBI chr 7:86,202,345...86,325,050
Ensembl chr 7:86,202,350...86,324,827
G
Epha2
Eph receptor A2
decreases expression
ISO
bexarotene results in decreased expression of EPHA2 mRNA
CTD
PMID:17178900
NCBI chr 5:153,605,644...153,634,115
Ensembl chr 5:153,605,644...153,634,117
G
Ephx1
epoxide hydrolase 1
increases expression
EXP
bexarotene results in increased expression of EPHX1 mRNA
CTD
PMID:23292798
NCBI chr13:92,714,315...92,744,124
Ensembl chr13:92,714,315...92,790,235
G
Ephx2
epoxide hydrolase 2
increases expression
EXP
bexarotene results in increased expression of EPHX2 mRNA
CTD
PMID:23292798
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
G
Erp29
endoplasmic reticulum protein 29
increases expression
EXP
bexarotene results in increased expression of ERP29 mRNA
CTD
PMID:16648578
NCBI chr12:35,089,698...35,095,952
Ensembl chr12:35,089,707...35,096,376
G
Esr1
estrogen receptor 1
decreases expression
ISO
bexarotene results in decreased expression of ESR1 mRNA
CTD
PMID:17849452
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
G
Esr2
estrogen receptor 2
multiple interactions
ISO
bexarotene binds to and results in decreased activity of ESR2 protein
CTD
PMID:25752796
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
G
F2
coagulation factor II
decreases expression
EXP
bexarotene results in decreased expression of F2 mRNA
CTD
PMID:16648578
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
G
Fabp1
fatty acid binding protein 1
decreases expression
EXP
bexarotene results in decreased expression of FABP1 mRNA
CTD
PMID:16648578
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
G
Fabp2
fatty acid binding protein 2
decreases expression multiple interactions
EXP
bexarotene results in decreased expression of FABP2 mRNA [Tamoxifen co-treated with bexarotene] results in decreased expression of FABP2 mRNA
CTD
PMID:17630414
NCBI chr 2:211,040,032...211,044,089
Ensembl chr 2:211,040,032...211,044,089
G
Fabp3
fatty acid binding protein 3
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of FABP3 mRNA
CTD
PMID:17630414
NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718
G
Fabp4
fatty acid binding protein 4
increases expression
ISO
bexarotene results in increased expression of FABP4 mRNA; bexarotene results in increased expression of FABP4 protein
CTD
PMID:21622945 PMID:25932594
NCBI chr 2:91,580,858...91,585,578
Ensembl chr 2:91,580,885...91,585,578
G
Fads2
fatty acid desaturase 2
increases expression multiple interactions
EXP
bexarotene results in increased expression of FADS2 mRNA [Tamoxifen co-treated with bexarotene] results in increased expression of FADS2 mRNA
CTD
PMID:17630414
NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789
G
Fam13a
family with sequence similarity 13, member A
decreases expression
EXP
bexarotene results in decreased expression of FAM13A mRNA
CTD
PMID:17630414
NCBI chr 4:88,056,521...88,155,782
Ensembl chr 4:88,058,403...88,155,860
G
Fasn
fatty acid synthase
multiple interactions increases expression
EXP ISO
[Tamoxifen co-treated with bexarotene] results in increased expression of FASN mRNA [Bexarotene co-treated with GW 3965] results in increased expression of FASN mRNA; [Bexarotene co-treated with paxilline] results in increased expression of FASN mRNA; [Bexarotene co-treated with T0901317] results in increased expression of FASN mRNA bexarotene results in increased expression of FASN mRNA
CTD
PMID:16648578 PMID:17630414 PMID:32123961
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
G
Fcgr2a
Fc gamma receptor 2A
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of FCGR3 mRNA
CTD
PMID:17630414
NCBI chr13:83,280,782...83,297,535
Ensembl chr13:83,280,784...83,295,967
G
Fcgr2b
Fc gamma receptor 2B
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of FCGR2B mRNA
CTD
PMID:17630414
NCBI chr13:83,191,253...83,207,776
Ensembl chr13:83,193,163...83,207,778
G
Fcna
ficolin A
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of FCNA mRNA
CTD
PMID:17630414
NCBI chr 3:8,445,904...8,449,128
Ensembl chr 3:8,445,907...8,449,105
G
Fdft1
farnesyl diphosphate farnesyl transferase 1
increases expression
EXP
bexarotene results in increased expression of FDFT1 mRNA
CTD
PMID:16648578
NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287
G
Fga
fibrinogen alpha chain
decreases expression
EXP
bexarotene results in decreased expression of FGA mRNA
CTD
PMID:16648578
NCBI chr 2:168,365,364...168,381,533
Ensembl chr 2:168,374,120...168,381,528
G
Fgb
fibrinogen beta chain
decreases expression
EXP
bexarotene results in decreased expression of FGB mRNA
CTD
PMID:16648578
NCBI chr 2:168,394,901...168,402,863
Ensembl chr 2:168,394,916...168,405,979
G
Fgg
fibrinogen gamma chain
decreases expression
EXP
bexarotene results in decreased expression of FGG mRNA
CTD
PMID:16648578
NCBI chr 2:168,354,880...168,362,325
Ensembl chr 2:168,355,013...168,362,322
G
Fh
fumarate hydratase
decreases expression
EXP
bexarotene results in decreased expression of FH1 mRNA
CTD
PMID:16648578
NCBI chr13:87,524,331...87,550,215
Ensembl chr13:87,524,337...87,550,266
G
Fmo1
flavin containing dimethylaniline monoxygenase 1
decreases expression
EXP
bexarotene results in decreased expression of FMO1 mRNA
CTD
PMID:16648578
NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647
G
Fn1
fibronectin 1
increases expression
EXP
bexarotene results in increased expression of FN1 mRNA
CTD
PMID:16648578
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
G
Foxa1
forkhead box A1
increases expression
EXP
bexarotene results in increased expression of FOXA1 mRNA
CTD
PMID:16648578
NCBI chr 6:75,099,907...75,136,534
Ensembl chr 6:75,103,503...75,136,188
G
Foxa2
forkhead box A2
decreases expression
EXP
bexarotene results in decreased expression of FOXA2 mRNA
CTD
PMID:16648578
NCBI chr 3:135,470,123...135,474,326
Ensembl chr 3:135,470,131...135,474,326
G
Galr2
galanin receptor 2
increases expression
EXP
bexarotene results in increased expression of GALR2 mRNA
CTD
PMID:16648578
NCBI chr10:101,513,689...101,517,176
Ensembl chr10:101,514,471...101,517,176
G
Gars1
glycyl-tRNA synthetase 1
decreases expression
ISO
Bexarotene results in decreased expression of GARS1 mRNA
CTD
PMID:17178900
NCBI chr 4:84,171,596...84,212,609
Ensembl chr 4:84,171,596...84,212,609
G
Gas6
growth arrest specific 6
decreases expression multiple interactions
EXP
bexarotene results in decreased expression of GAS6 mRNA [bexarotene co-treated with Tamoxifen] results in decreased expression of GAS6 mRNA
CTD
PMID:16648578 PMID:17630414
NCBI chr16:76,045,430...76,075,904
Ensembl chr16:76,045,426...76,075,904
G
Gas7
growth arrest specific 7
increases expression
EXP
bexarotene results in increased expression of GAS7 mRNA
CTD
PMID:16648578
NCBI chr10:52,152,728...52,383,276
Ensembl chr10:52,152,493...52,383,276
G
Gc
GC, vitamin D binding protein
decreases expression
EXP
bexarotene results in decreased expression of GC mRNA
CTD
PMID:16648578
NCBI chr14:18,632,146...18,667,563
Ensembl chr14:18,632,135...18,667,567
G
Gcgr
glucagon receptor
decreases expression
EXP
bexarotene results in decreased expression of GCGR mRNA
CTD
PMID:16648578
NCBI chr10:105,808,474...105,816,641
Ensembl chr10:105,808,473...105,816,640
G
Ghrh
growth hormone releasing hormone
increases expression
EXP
bexarotene results in increased expression of GHRH mRNA
CTD
PMID:16648578
NCBI chr 3:145,992,762...146,012,528
Ensembl chr 3:145,992,763...146,011,889
G
Glra3
glycine receptor, alpha 3
increases expression
EXP
bexarotene results in increased expression of GLRA3 mRNA
CTD
PMID:16648578
NCBI chr16:34,205,431...34,848,332
Ensembl chr16:34,204,811...34,848,753
G
Gosr1
golgi SNAP receptor complex member 1
increases expression
EXP
bexarotene results in increased expression of GOSR1 mRNA
CTD
PMID:16648578
NCBI chr10:61,570,499...61,607,287
Ensembl chr10:61,450,494...61,607,177 Ensembl chr10:61,450,494...61,607,177
G
Gpd1
glycerol-3-phosphate dehydrogenase 1
increases expression
EXP
bexarotene results in increased expression of GPD1 mRNA
CTD
PMID:23292798
NCBI chr 7:130,842,526...130,851,530
Ensembl chr 7:130,844,138...130,851,529
G
Gpd2
glycerol-3-phosphate dehydrogenase 2
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of GPD2 mRNA
CTD
PMID:17630414
NCBI chr 3:41,800,552...41,937,729
Ensembl chr 3:41,801,930...41,936,901
G
Gpm6a
glycoprotein m6a
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of GPM6A mRNA
CTD
PMID:17630414
NCBI chr16:36,641,282...36,973,477
Ensembl chr16:36,641,284...36,973,475
G
Gpm6b
glycoprotein m6b
increases expression
ISO
bexarotene results in increased expression of GPM6B mRNA
CTD
PMID:17178900
NCBI chr X:28,057,788...28,204,409
Ensembl chr X:28,059,450...28,204,211
G
Gpx4
glutathione peroxidase 4
increases expression
EXP
bexarotene results in increased expression of GPX4 mRNA
CTD
PMID:16648578
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
G
Grin2c
glutamate ionotropic receptor NMDA type subunit 2C
increases expression
EXP
bexarotene results in increased expression of GRIN2C mRNA
CTD
PMID:17630414
NCBI chr10:100,488,430...100,507,083
Ensembl chr10:100,488,431...100,506,427
G
Grina
glutamate ionotropic receptor NMDA type subunit associated protein 1
increases expression
EXP
bexarotene results in increased expression of GRINA mRNA
CTD
PMID:16648578
NCBI chr 7:107,962,194...107,965,368
Ensembl chr 7:107,962,207...107,965,366
G
Grk2
G protein-coupled receptor kinase 2
increases expression
EXP
bexarotene results in increased expression of GRK2 mRNA
CTD
PMID:16648578
NCBI chr 1:201,581,480...201,601,580
Ensembl chr 1:201,581,480...201,601,582
G
Gsta5
glutathione S-transferase alpha 5
increases expression
EXP
bexarotene results in increased expression of GSTA5 mRNA
CTD
PMID:23292798
NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472
G
Gstm6
glutathione S-transferase, mu 6
increases expression
EXP
Bexarotene results in increased expression of GSTM5 mRNA
CTD
PMID:17630414
NCBI chr 2:195,579,566...195,584,340
Ensembl chr 2:195,544,426...195,628,961
G
Gys2
glycogen synthase 2
decreases expression increases expression
EXP
bexarotene results in decreased expression of GYS2 mRNA bexarotene results in increased expression of GYS2 mRNA
CTD
PMID:16648578 PMID:23292798
NCBI chr 4:175,365,054...175,406,228
Ensembl chr 4:175,365,054...175,406,228
G
H2az1
H2A.Z variant histone 1
decreases expression
EXP
Bexarotene results in decreased expression of H2AZ1 mRNA
CTD
PMID:16648578
NCBI chr 2:226,355,769...226,357,878
Ensembl chr 2:226,355,708...226,358,485
G
Hao2
hydroxyacid oxidase 2
decreases expression
EXP
bexarotene results in decreased expression of HAO2 mRNA
CTD
PMID:17630414
NCBI chr 2:186,200,137...186,232,997
Ensembl chr 2:186,200,504...186,224,425
G
Herpud1
homocysteine inducible ER protein with ubiquitin like domain 1
decreases expression
ISO
bexarotene results in decreased expression of HERPUD1 mRNA
CTD
PMID:17178900
NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424
G
Hmgb2
high mobility group box 2
decreases expression
EXP
bexarotene results in decreased expression of HMGB2 mRNA
CTD
PMID:16648578
NCBI chr16:32,710,651...32,713,230
Ensembl chr16:32,710,658...32,713,140
G
Homer1
homer scaffold protein 1
increases expression
EXP
bexarotene results in increased expression of HOMER1 mRNA
CTD
PMID:16648578
NCBI chr 2:24,542,777...24,645,715
Ensembl chr 2:24,543,093...24,644,785
G
Hp
haptoglobin
decreases expression
EXP
bexarotene results in decreased expression of HP mRNA
CTD
PMID:16648578
NCBI chr19:37,539,626...37,544,178
Ensembl chr19:37,539,627...37,544,523
G
Hpgds
hematopoietic prostaglandin D synthase
increases expression
EXP
bexarotene results in increased expression of HPGDS mRNA
CTD
PMID:16648578
NCBI chr 4:94,368,426...94,397,931
Ensembl chr 4:94,373,342...94,397,883
G
Hsd11b2
hydroxysteroid 11-beta dehydrogenase 2
increases expression multiple interactions
ISO
Bexarotene results in increased expression of HSD11B2 mRNA Bexarotene results in increased expression of and results in increased activity of HSD11B2 protein; Cycloheximide promotes the reaction [Bexarotene results in increased expression of HSD11B2 mRNA]; Dactinomycin inhibits the reaction [Bexarotene results in increased expression of HSD11B2 mRNA]; LG 100754 inhibits the reaction [Bexarotene results in increased activity of HSD11B2 protein]; RXRA protein affects the reaction [Bexarotene results in increased expression of HSD11B2 mRNA]; RXRA protein affects the reaction [Bexarotene results in increased expression of HSD11B2 protein]
CTD
PMID:31927052
NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899
G
Hsd17b12
hydroxysteroid (17-beta) dehydrogenase 12
increases expression
EXP
bexarotene results in increased expression of HSD17B12 mRNA
CTD
PMID:16648578
NCBI chr 3:79,990,048...80,113,556
Ensembl chr 3:79,990,056...80,113,617
G
Hsd17b2
hydroxysteroid (17-beta) dehydrogenase 2
decreases expression
EXP
bexarotene results in decreased expression of HSD17B2 mRNA
CTD
PMID:16648578
NCBI chr19:45,753,576...45,825,203
Ensembl chr19:45,753,574...45,825,202
G
Hspa4
heat shock protein family A (Hsp70) member 4
decreases expression
EXP
bexarotene results in decreased expression of HSPA4 mRNA
CTD
PMID:16648578
NCBI chr10:37,408,025...37,449,080
Ensembl chr10:37,408,025...37,449,001
G
Hspa9
heat shock protein family A (Hsp70) member 9
increases expression
EXP
bexarotene results in increased expression of HSPA9 mRNA
CTD
PMID:16648578
NCBI chr18:26,536,131...26,554,294
Ensembl chr18:26,535,798...26,554,292
G
Hspb1
heat shock protein family B (small) member 1
increases expression
EXP
bexarotene results in increased expression of HSPB1 mRNA
CTD
PMID:16648578
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
G
Hsph1
heat shock protein family H (Hsp110) member 1
decreases expression
EXP
bexarotene results in decreased expression of HSPH1 mRNA
CTD
PMID:16648578
NCBI chr12:5,390,916...5,410,224
Ensembl chr12:5,390,922...5,410,224
G
Id1
inhibitor of DNA binding 1, HLH protein
increases expression
ISO
bexarotene results in increased expression of ID1 mRNA; bexarotene results in increased expression of ID1 protein
CTD
PMID:17178900
NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419
G
Ier2
immediate early response 2
decreases expression
ISO
bexarotene results in decreased expression of IER2 mRNA
CTD
PMID:17178900
NCBI chr19:23,494,551...23,496,075
Ensembl chr19:23,494,184...23,499,211
G
Ifitm1
interferon induced transmembrane protein 1
multiple interactions
EXP
[Bexarotene co-treated with Tamoxifen] results in decreased expression of IFITM1 mRNA
CTD
PMID:17630414
NCBI chr 1:196,067,163...196,069,169
Ensembl chr 1:196,067,963...196,069,169
G
Ifngr1
interferon gamma receptor 1
increases expression
EXP
bexarotene results in increased expression of IFNGR1 mRNA
CTD
PMID:16648578
NCBI chr 1:14,333,167...14,351,799
Ensembl chr 1:14,333,187...14,351,785
G
Igf1
insulin-like growth factor 1
decreases expression
EXP
bexarotene results in decreased expression of IGF1 protein
CTD
PMID:15591091
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
G
Igf2
insulin-like growth factor 2
increases expression
EXP
bexarotene results in increased expression of IGF2 mRNA
CTD
PMID:16648578
NCBI chr 1:197,814,409...197,831,802
Ensembl chr 1:197,814,410...197,823,018
G
Igfbp1
insulin-like growth factor binding protein 1
increases expression
EXP
bexarotene results in increased expression of IGFBP1 mRNA
CTD
PMID:16648578
NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
G
Igfbp2
insulin-like growth factor binding protein 2
increases expression multiple interactions
EXP
bexarotene results in increased expression of IGFBP2 mRNA [Tamoxifen co-treated with bexarotene] results in increased expression of IGFBP2 mRNA
CTD
PMID:16648578 PMID:17630414
NCBI chr 9:74,415,574...74,442,945
Ensembl chr 9:74,415,546...74,442,937
G
Igfbp3
insulin-like growth factor binding protein 3
multiple interactions decreases expression
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of IGFBP3 mRNA bexarotene results in decreased expression of IGFBP3 mRNA
CTD
PMID:16648578 PMID:17630414
NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083
G
Igfbp6
insulin-like growth factor binding protein 6
increases expression
ISO
bexarotene results in increased expression of IGFBP6 mRNA; bexarotene results in increased expression of IGFBP6 protein
CTD
PMID:17178900
NCBI chr 7:133,276,309...133,280,944
Ensembl chr 7:133,276,234...133,280,966
G
Igfbp7
insulin-like growth factor binding protein 7
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of IGFBP7 mRNA
CTD
PMID:17630414
NCBI chr14:30,737,414...30,797,317
Ensembl chr14:30,737,164...30,797,314
G
Il15
interleukin 15
increases expression
ISO
bexarotene results in increased expression of IL15 mRNA
CTD
PMID:17178900
NCBI chr19:25,640,013...25,706,818
Ensembl chr19:25,640,251...25,706,820
G
Il18
interleukin 18
decreases expression
EXP
bexarotene results in decreased expression of IL18 mRNA
CTD
PMID:16648578
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
G
Il4
interleukin 4
decreases expression
ISO
bexarotene results in decreased expression of IL4 protein
CTD
PMID:15781672
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
G
Il6r
interleukin 6 receptor
decreases expression
EXP
bexarotene results in decreased expression of IL6RA mRNA
CTD
PMID:16648578
NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536
G
Ins2
insulin 2
multiple interactions
ISO
[bexarotene co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 protein; bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA]; bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; bexarotene promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA]; bexarotene promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SREBF1 mRNA] [[Dexamethasone co-treated with INS protein co-treated with 1-Methyl-3-isobutylxanthine] co-treated with bexarotene] results in increased expression of SLC27A1 mRNA; [Dexamethasone co-treated with INS protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased susceptibility to bexarotene
CTD
PMID:10777552 PMID:25932594
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
G
Insig1
insulin induced gene 1
increases expression
EXP
bexarotene results in increased expression of INSIG1 mRNA
CTD
PMID:16648578
NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952
G
Insrr
insulin receptor-related receptor
increases expression
EXP
bexarotene results in increased expression of INSRR mRNA
CTD
PMID:16648578
NCBI chr 2:173,255,335...173,274,800
Ensembl chr 2:173,255,414...173,274,800
G
Irf1
interferon regulatory factor 1
increases expression
EXP
bexarotene results in increased expression of IRF1 mRNA
CTD
PMID:16648578
NCBI chr10:37,917,155...37,924,166
Ensembl chr10:37,916,670...37,924,166
G
Itga7
integrin subunit alpha 7
decreases expression
EXP
bexarotene results in decreased expression of ITGA7 mRNA
CTD
PMID:16648578
NCBI chr 7:1,360,125...1,388,886
Ensembl chr 7:1,359,940...1,388,450
G
Itgb6
integrin subunit beta 6
increases expression
ISO
bexarotene results in increased expression of ITGB6 mRNA
CTD
PMID:17178900
NCBI chr 3:45,046,295...45,170,532
Ensembl chr 3:45,048,044...45,121,671
G
Itih3
inter-alpha trypsin inhibitor, heavy chain 3
decreases expression
EXP
bexarotene results in decreased expression of ITIH3 mRNA
CTD
PMID:16648578
NCBI chr16:6,101,922...6,117,154
Ensembl chr16:6,101,930...6,116,924
G
Itm2a
integral membrane protein 2A
increases expression
ISO
bexarotene results in increased expression of ITM2A mRNA
CTD
PMID:17178900
NCBI chr X:72,486,383...72,492,344
Ensembl chr X:72,486,381...72,492,363
G
Itpr1
inositol 1,4,5-trisphosphate receptor, type 1
increases expression
ISO
bexarotene results in increased expression of ITPR1 mRNA
CTD
PMID:17178900
NCBI chr 4:141,187,377...141,554,240
Ensembl chr 4:141,187,418...141,510,491
G
Ivl
involucrin
decreases expression
ISO
bexarotene results in decreased expression of IVL mRNA
CTD
PMID:8853895
NCBI chr 2:178,146,694...178,160,807
Ensembl chr 2:178,147,061...178,149,100
G
Jup
junction plakoglobin
increases expression
EXP
bexarotene results in increased expression of JUP mRNA
CTD
PMID:16648578
NCBI chr10:85,300,438...85,327,378
Ensembl chr10:85,300,440...85,327,057
G
Kcnma1
potassium calcium-activated channel subfamily M alpha 1
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of KCNMA1 mRNA
CTD
PMID:17630414
NCBI chr15:302,078...1,001,198
Ensembl chr15:302,214...1,001,198
G
Kcnt1
potassium sodium-activated channel subfamily T member 1
increases expression
EXP
bexarotene results in increased expression of KCNT1 mRNA
CTD
PMID:16648578
NCBI chr 3:8,682,964...8,736,615
Ensembl chr 3:8,682,113...8,736,667
G
Klf10
Kruppel-like factor 10
decreases expression
ISO
bexarotene results in decreased expression of KLF10 mRNA
CTD
PMID:17178900
NCBI chr 7:69,467,658...69,473,726
Ensembl chr 7:69,465,619...69,473,994
G
Klf9
Kruppel-like factor 9
increases expression decreases expression
ISO EXP
bexarotene results in increased expression of KLF9 mRNA bexarotene results in decreased expression of KLF9 mRNA
CTD
PMID:16648578 PMID:26096596
NCBI chr 1:220,700,108...220,725,029
Ensembl chr 1:220,700,108...220,725,037
G
Kng2
kininogen 2
increases expression decreases expression
ISO EXP
bexarotene results in increased expression of KNG1 mRNA bexarotene results in decreased expression of KNG1 mRNA
CTD
PMID:16648578 PMID:17849452
NCBI chr11:77,913,876...77,936,247
Ensembl chr11:77,909,612...78,002,971
G
Krt14
keratin 14
decreases expression
ISO
bexarotene results in decreased expression of KRT14 mRNA
CTD
PMID:8853895
NCBI chr10:85,137,932...85,141,990
Ensembl chr10:85,066,802...85,171,799
G
Krt15
keratin 15
increases expression
ISO
bexarotene results in increased expression of KRT15 mRNA
CTD
PMID:17178900
NCBI chr10:85,066,797...85,070,614
Ensembl chr10:85,066,802...85,171,799
G
Krt17
keratin 17
decreases expression
ISO
bexarotene results in decreased expression of KRT17 mRNA; bexarotene results in decreased expression of KRT17 protein
CTD
PMID:17178900
NCBI chr10:85,178,673...85,183,392
Ensembl chr10:85,178,675...85,183,392
G
Krt5
keratin 5
decreases expression
ISO
bexarotene results in decreased expression of KRT5 mRNA
CTD
PMID:8853895
NCBI chr 7:132,846,355...132,851,986
Ensembl chr 7:132,846,136...132,851,850
G
Ldhb
lactate dehydrogenase B
decreases expression
EXP
bexarotene results in decreased expression of LDHB mRNA
CTD
PMID:16648578
NCBI chr 4:175,428,382...175,446,403
Ensembl chr 4:175,428,385...175,446,403
G
Lgals3
galectin 3
decreases expression
EXP
bexarotene results in decreased expression of LGALS3 mRNA
CTD
PMID:16648578
NCBI chr15:20,620,083...20,632,019
Ensembl chr15:20,607,692...20,632,025
G
Lgals5
galectin 5
increases expression
EXP
bexarotene results in increased expression of LGALS5 mRNA
CTD
PMID:16648578
NCBI chr10:63,853,949...63,857,198
Ensembl chr10:63,853,935...63,857,153
G
Lifr
LIF receptor subunit alpha
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of LIFR mRNA
CTD
PMID:17630414
NCBI chr 2:56,224,393...56,292,988
Ensembl chr 2:56,250,120...56,286,699
G
Lipa
lipase A, lysosomal acid type
decreases expression
EXP
bexarotene results in decreased expression of LIP1 mRNA
CTD
PMID:16648578
NCBI chr 1:232,024,351...232,167,329
Ensembl chr 1:232,024,356...232,057,633
G
Lipe
lipase E, hormone sensitive type
decreases expression
EXP
bexarotene results in decreased expression of LIPE mRNA
CTD
PMID:16648578
NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310
G
Lman1
lectin, mannose-binding, 1
decreases expression
EXP
bexarotene results in decreased expression of LMAN1 mRNA
CTD
PMID:16648578
NCBI chr18:59,508,996...59,530,873
Ensembl chr18:59,508,996...59,530,851
G
LOC102556347
carbonyl reductase [NADPH] 1-like
increases expression
EXP
Bexarotene results in increased expression of CBR1 mRNA
CTD
PMID:16648578
NCBI chr11:32,892,640...32,895,277
Ensembl chr11:32,857,991...32,895,275
G
Lox
lysyl oxidase
decreases expression
EXP
bexarotene results in decreased expression of LOX mRNA
CTD
PMID:16648578
NCBI chr18:45,964,311...46,041,477
Ensembl chr18:45,967,343...46,041,477
G
Loxl2
lysyl oxidase-like 2
increases expression
ISO
bexarotene results in increased expression of LOXL2 mRNA
CTD
PMID:17178900
NCBI chr15:44,683,449...44,773,067
Ensembl chr15:44,683,880...44,773,067
G
Lre3
LINE retrotransposable element 3
increases expression
EXP
bexarotene results in increased expression of LRE3 mRNA
CTD
PMID:16648578
G
Lrg1
leucine-rich alpha-2-glycoprotein 1
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of LRG1 mRNA
CTD
PMID:17630414
NCBI chr 9:947,516...949,773
Ensembl chr 9:947,516...949,813
G
Lrp2
LDL receptor related protein 2
decreases expression
EXP
bexarotene results in decreased expression of LRP2 mRNA
CTD
PMID:16648578
NCBI chr 3:54,189,305...54,346,769
Ensembl chr 3:54,189,308...54,346,708
G
Lum
lumican
decreases expression
EXP
bexarotene results in decreased expression of LUM mRNA
CTD
PMID:16648578
NCBI chr 7:32,358,990...32,365,794
Ensembl chr 7:32,358,614...32,365,793
G
Lypla1
lysophospholipase 1
decreases expression
EXP
bexarotene results in decreased expression of LYPLA1 mRNA
CTD
PMID:16648578
NCBI chr 5:14,679,605...14,708,774
Ensembl chr 5:14,679,606...14,708,746
G
Lyst
lysosomal trafficking regulator
increases expression
EXP
bexarotene results in increased expression of LYST mRNA
CTD
PMID:17630414
NCBI chr17:86,241,384...86,443,501
Ensembl chr17:86,241,384...86,443,480
G
Lyve1
lymphatic vessel endothelial hyaluronan receptor 1
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of XLKD1 mRNA
CTD
PMID:17630414
NCBI chr 1:164,962,872...164,976,309
Ensembl chr 1:164,962,872...164,976,309
G
Maf
MAF bZIP transcription factor
increases expression
ISO
bexarotene results in increased expression of MAF mRNA
CTD
PMID:17178900
NCBI chr19:43,353,867...43,713,162
Ensembl chr19:43,360,342...43,712,365
G
Maff
MAF bZIP transcription factor F
decreases expression
ISO
bexarotene results in decreased expression of MAFF mRNA
CTD
PMID:17178900
NCBI chr 7:110,912,499...110,923,851
Ensembl chr 7:110,912,499...110,923,851
G
Maob
monoamine oxidase B
decreases expression
EXP
bexarotene results in decreased expression of MAOB mRNA
CTD
PMID:16648578
NCBI chr X:5,907,327...6,010,996
Ensembl chr X:5,907,266...6,011,003
G
Map1b
microtubule-associated protein 1B
increases expression
EXP
bexarotene results in increased expression of MAP1B mRNA
CTD
PMID:16648578
NCBI chr 2:30,817,261...30,910,458
Ensembl chr 2:30,817,261...30,910,317
G
Map2
microtubule-associated protein 2
increases expression
EXP
bexarotene results in increased expression of MAP2 mRNA
CTD
PMID:16648578
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
G
Map3k1
mitogen-activated protein kinase kinase kinase 1
increases expression
EXP
bexarotene results in increased expression of MAP3K1 mRNA
CTD
PMID:16648578
NCBI chr 2:43,348,572...43,414,706
Ensembl chr 2:43,350,098...43,414,463
G
Map3k12
mitogen activated protein kinase kinase kinase 12
increases expression
EXP
bexarotene results in increased expression of MAP3K12 mRNA
CTD
PMID:16648578
NCBI chr 7:133,630,267...133,648,464
Ensembl chr 7:133,630,835...133,640,789
G
Mark1
microtubule affinity regulating kinase 1
increases expression
EXP
bexarotene results in increased expression of MARK1 mRNA
CTD
PMID:16648578
NCBI chr13:96,450,189...96,555,304
Ensembl chr13:96,451,487...96,555,173
G
Me1
malic enzyme 1
increases expression
EXP
bexarotene results in increased expression of ME1 mRNA
CTD
PMID:16648578 PMID:23292798
NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304
G
Mfsd2a
major facilitator superfamily domain containing 2A
decreases expression
EXP
bexarotene results in decreased expression of MFSD2A mRNA
CTD
PMID:17630414
NCBI chr 5:135,225,801...135,240,744
Ensembl chr 5:135,225,816...135,240,690
G
Mgp
matrix Gla protein
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of MGP mRNA
CTD
PMID:17630414
NCBI chr 4:169,766,290...169,769,612
Ensembl chr 4:169,766,279...169,769,667
G
Mllt11
MLLT11, transcription factor 7 cofactor
increases expression
ISO
bexarotene results in increased expression of MLLT11 mRNA
CTD
PMID:17178900
NCBI chr 2:182,795,790...182,804,960
Ensembl chr 2:182,795,790...182,797,199
G
Mlxipl
MLX interacting protein-like
multiple interactions
ISO
[Bexarotene co-treated with GW 3965] results in decreased expression of MLXIPL mRNA; [Bexarotene co-treated with T0901317] results in decreased expression of MLXIPL mRNA
CTD
PMID:32123961
NCBI chr12:21,542,964...21,577,120
Ensembl chr12:21,543,576...21,577,112
G
Mmp1
matrix metallopeptidase 1
decreases expression
ISO
bexarotene results in decreased expression of MMP1 mRNA
CTD
PMID:17178900
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
G
Mmp14
matrix metallopeptidase 14
decreases expression
EXP
bexarotene results in decreased expression of MMP14 mRNA
CTD
PMID:16648578
NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864
G
Mrc1
mannose receptor, C type 1
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of MRC1 mRNA
CTD
PMID:17630414
NCBI chr17:77,249,187...77,330,857
Ensembl chr17:77,249,187...77,330,857
G
Mt-co2
mitochondrially encoded cytochrome c oxidase II
decreases expression
ISO
bexarotene results in decreased expression of COX2 mRNA; bexarotene results in decreased expression of COX2 protein
CTD
PMID:17178900
NCBI chr MT:7,006...7,689
Ensembl chr MT:7,006...7,689
G
Mthfd2
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase
decreases expression
ISO
bexarotene results in decreased expression of MTHFD2 mRNA
CTD
PMID:17178900
NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608
G
Muc1
mucin 1, cell surface associated
increases expression
EXP
bexarotene results in increased expression of MUC1 mRNA
CTD
PMID:16648578
NCBI chr 2:174,635,559...174,640,738
Ensembl chr 2:174,635,995...174,640,733
G
Mug1
murinoglobulin 1
decreases expression
EXP
bexarotene results in decreased expression of MUG1 mRNA
CTD
PMID:16648578
NCBI chr 4:155,076,270...155,130,051
Ensembl chr 4:155,076,312...155,130,051
G
Napa
NSF attachment protein alpha
increases expression
EXP
bexarotene results in increased expression of NAPA mRNA
CTD
PMID:16648578
NCBI chr 1:76,787,036...76,805,869
Ensembl chr 1:76,786,932...76,805,869
G
Nat8
N-acetyltransferase 8
decreases expression
EXP
bexarotene results in decreased expression of NAT8 mRNA
CTD
PMID:17630414
NCBI chr 4:118,279,521...118,284,671
Ensembl chr 4:118,270,954...118,281,763
G
Ndufaf3
NADH:ubiquinone oxidoreductase complex assembly factor 3
increases expression
EXP
bexarotene results in increased expression of NDUFAF3 mRNA
CTD
PMID:16648578
NCBI chr 8:109,261,362...109,263,194
Ensembl chr 8:109,261,363...109,263,194
G
Neurod2
neuronal differentiation 2
increases expression
EXP
bexarotene results in increased expression of NEUROD2 mRNA
CTD
PMID:16648578
NCBI chr10:83,323,801...83,327,986
Ensembl chr10:83,324,442...83,327,986
G
Nim1k
NIM1 serine/threonine protein kinase
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of NIM1K mRNA
CTD
PMID:17630414
NCBI chr 2:51,670,764...51,714,782
Ensembl chr 2:51,670,772...51,714,762
G
Nol3
nucleolar protein 3
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of NOL3 mRNA
CTD
PMID:17630414
NCBI chr19:33,154,061...33,158,250
Ensembl chr19:33,154,062...33,158,250
G
Nos2
nitric oxide synthase 2
decreases expression
ISO
bexarotene results in decreased expression of NOS2 mRNA
CTD
PMID:17849452
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
G
Npy
neuropeptide Y
increases expression
EXP
bexarotene results in increased expression of NPY mRNA
CTD
PMID:17630414
NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495
G
Nr0b2
nuclear receptor subfamily 0, group B, member 2
increases expression multiple interactions
EXP ISO
bexarotene results in increased expression of NR0B2 mRNA [Bexarotene co-treated with GW 3965] results in increased expression of NR0B2 mRNA; [Bexarotene co-treated with paxilline] results in increased expression of NR0B2 mRNA; [Bexarotene co-treated with T0901317] results in increased expression of NR0B2 mRNA Bexarotene results in increased expression of NR0B2 mRNA
CTD
PMID:17630414 PMID:23292798 PMID:32123961
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
G
Nr1h3
nuclear receptor subfamily 1, group H, member 3
multiple interactions decreases expression
ISO
[Bexarotene co-treated with GW 3965] results in increased expression of NR1H3 mRNA; [Bexarotene co-treated with paxilline] results in increased expression of NR1H3 mRNA; [Bexarotene co-treated with T0901317] results in increased expression of NR1H3 mRNA; Bexarotene promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA] Bexarotene results in decreased expression of NR1H3 mRNA
CTD
PMID:25932594 PMID:32123961
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
G
Nr1i3
nuclear receptor subfamily 1, group I, member 3
increases expression multiple interactions
EXP ISO
bexarotene results in increased expression of NR1I3 mRNA Bexarotene binds to and results in increased activity of NR1I3 protein alternative form
CTD
PMID:17630414 PMID:31312845
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
G
Nrip1
nuclear receptor interacting protein 1
multiple interactions
ISO
[Bexarotene co-treated with GW 3965] results in increased expression of NRIP1 mRNA; [Bexarotene co-treated with T0901317] results in increased expression of NRIP1 mRNA
CTD
PMID:32123961
NCBI chr11:14,895,843...14,979,490
Ensembl chr11:14,895,553...14,981,761
G
Oaz1
ornithine decarboxylase antizyme 1
increases expression
EXP
bexarotene results in increased expression of OAZ1 mRNA
CTD
PMID:16648578
NCBI chr 7:8,883,855...8,886,315
Ensembl chr 7:8,883,851...8,886,310
G
Odc1
ornithine decarboxylase 1
decreases expression
ISO
bexarotene results in decreased expression of ODC1 mRNA
CTD
PMID:17178900
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
G
Odf3b
outer dense fiber of sperm tails 3B
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of ODF3B mRNA
CTD
PMID:17630414
NCBI chr 7:120,444,232...120,447,383
Ensembl chr 7:120,444,232...120,446,749
G
Olr1280
olfactory receptor 1280
increases expression
EXP
bexarotene results in increased expression of OLR1280 mRNA
CTD
PMID:16648578
NCBI chr 8:39,282,393...39,283,352
Ensembl chr 8:39,282,325...39,292,365
G
Orm1
orosomucoid 1
decreases expression
EXP
bexarotene results in decreased expression of ORM1 mRNA
CTD
PMID:16648578
NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154
G
P4hb
prolyl 4-hydroxylase subunit beta
increases expression
EXP
bexarotene results in increased expression of P4HB mRNA
CTD
PMID:16648578
NCBI chr10:105,836,972...105,848,583
Ensembl chr10:105,836,982...105,848,500
G
Pde2a
phosphodiesterase 2A
decreases expression
EXP
bexarotene results in decreased expression of PDE2A mRNA
CTD
PMID:16648578
NCBI chr 1:155,823,590...155,915,434
Ensembl chr 1:155,813,180...155,915,434
G
Pdk2
pyruvate dehydrogenase kinase 2
increases expression
EXP
bexarotene results in increased expression of PDK2 mRNA
CTD
PMID:16648578
NCBI chr10:79,972,550...79,987,074
Ensembl chr10:79,972,556...79,987,085
G
Pdk4
pyruvate dehydrogenase kinase 4
increases expression
EXP
bexarotene results in increased expression of PDK4 mRNA
CTD
PMID:16648578
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
G
Per2
period circadian regulator 2
decreases expression
ISO
bexarotene results in decreased expression of PER2 mRNA
CTD
PMID:17178900
NCBI chr 9:92,007,289...92,049,551
Ensembl chr 9:92,007,296...92,049,459
G
Pex11a
peroxisomal biogenesis factor 11 alpha
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of PEX11A mRNA
CTD
PMID:17630414
NCBI chr 1:133,680,091...133,687,172
Ensembl chr 1:133,680,091...133,687,172
G
Pex19
peroxisomal biogenesis factor 19
decreases expression
EXP
bexarotene results in decreased expression of PEX19 mRNA
CTD
PMID:16648578
NCBI chr13:84,592,277...84,608,793
Ensembl chr13:84,592,312...84,608,608
G
Pf4
platelet factor 4
increases expression
EXP
bexarotene results in increased expression of PF4 mRNA
CTD
PMID:17630414
NCBI chr14:17,298,438...17,299,148
Ensembl chr14:17,298,308...17,299,365
G
Pgr
progesterone receptor
multiple interactions
ISO
bexarotene binds to and results in decreased activity of PGR protein
CTD
PMID:25752796
NCBI chr 8:6,073,216...6,131,552
Ensembl chr 8:6,072,673...6,131,344
G
Pik3cb
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta
increases expression
EXP
bexarotene results in increased expression of PIK3CB mRNA
CTD
PMID:16648578
NCBI chr 8:99,594,600...99,699,772
Ensembl chr 8:99,594,644...99,699,663
G
Pik3r1
phosphoinositide-3-kinase regulatory subunit 1
multiple interactions
ISO
bexarotene promotes the reaction [rosiglitazone results in increased expression of PIK3R1 mRNA]
CTD
PMID:10548525
NCBI chr 2:32,878,942...32,963,611
Ensembl chr 2:32,882,032...32,963,631
G
Pik3r3
phosphoinositide-3-kinase regulatory subunit 3
increases expression
EXP
bexarotene results in increased expression of PIK3R3 mRNA
CTD
PMID:16648578
NCBI chr 5:129,700,925...129,772,591
Ensembl chr 5:129,701,229...129,772,583
G
Pkib
cAMP-dependent protein kinase inhibitor beta
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of PKIB mRNA
CTD
PMID:17630414
NCBI chr20:36,965,172...37,062,190
Ensembl chr20:36,905,340...37,062,187
G
Plagl1
PLAG1 like zinc finger 1
decreases expression
EXP
bexarotene results in decreased expression of PLAGL1 mRNA
CTD
PMID:16648578
NCBI chr 1:7,477,295...7,517,229
Ensembl chr 1:7,477,177...7,517,228
G
Plat
plasminogen activator, tissue type
increases expression
ISO
bexarotene results in increased expression of PLAT mRNA
CTD
PMID:17178900
NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223
G
Plaur
plasminogen activator, urokinase receptor
decreases expression
ISO
bexarotene results in decreased expression of PLAUR mRNA
CTD
PMID:17178900
NCBI chr 1:80,053,441...80,068,384
Ensembl chr 1:80,050,324...80,068,595
G
Plin1
perilipin 1
increases expression
ISO
bexarotene results in increased expression of PLIN1 mRNA
CTD
PMID:25932594
NCBI chr 1:133,664,294...133,676,854
Ensembl chr 1:133,664,892...133,676,828
G
Plod2
procollagen lysine, 2-oxoglutarate 5-dioxygenase 2
increases expression
ISO
bexarotene results in increased expression of PLOD2 mRNA
CTD
PMID:17178900
NCBI chr 8:93,084,548...93,167,255
Ensembl chr 8:93,084,513...93,167,255
G
Pno1
partner of NOB1 homolog
decreases expression
ISO
bexarotene results in decreased expression of PNO1 mRNA
CTD
PMID:17178900
NCBI chr14:91,609,711...91,618,280
Ensembl chr14:91,609,233...91,618,324
G
Pnrc1
proline-rich nuclear receptor coactivator 1
increases expression
ISO
bexarotene results in increased expression of PNRC1 mRNA
CTD
PMID:17178900
NCBI chr 5:47,647,070...47,657,832
Ensembl chr 5:47,647,071...47,650,161
G
Pola1
DNA polymerase alpha 1, catalytic subunit
increases expression
EXP
bexarotene results in increased expression of POLA1 mRNA
CTD
PMID:16648578
NCBI chr X:58,034,617...58,348,612
Ensembl chr X:58,034,619...58,348,536
G
Pon1
paraoxonase 1
decreases expression
EXP
bexarotene results in decreased expression of PON1 mRNA
CTD
PMID:16648578
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
G
Por
cytochrome p450 oxidoreductase
increases expression
EXP
bexarotene results in increased expression of POR mRNA
CTD
PMID:16648578
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
G
Ppp2cb
protein phosphatase 2 catalytic subunit beta
increases expression
EXP
bexarotene results in increased expression of PPP2CB mRNA
CTD
PMID:16648578
NCBI chr16:58,558,119...58,579,325
Ensembl chr16:58,558,122...58,579,576
G
Ppp2r1a
protein phosphatase 2 scaffold subunit A alpha
increases expression
EXP
bexarotene results in increased expression of PPP2R1A mRNA
CTD
PMID:16648578
NCBI chr 1:60,540,223...60,559,467
Ensembl chr 1:60,540,194...60,560,129
G
Ppt1
palmitoyl-protein thioesterase 1
decreases expression
EXP
bexarotene results in decreased expression of PPT1 mRNA
CTD
PMID:16648578
NCBI chr 5:135,121,176...135,141,076
Ensembl chr 5:135,121,163...135,142,048
G
Prdx6
peroxiredoxin 6
increases expression
EXP
bexarotene results in increased expression of PRDX6 mRNA
CTD
PMID:16648578
NCBI chr13:73,528,746...73,539,295
Ensembl chr13:73,528,210...73,539,355
G
Prkar2b
protein kinase cAMP-dependent type II regulatory subunit beta
decreases expression
EXP
bexarotene results in decreased expression of PRKAR2B mRNA
CTD
PMID:16648578
NCBI chr 6:48,563,659...48,653,933
Ensembl chr 6:48,563,662...48,653,933
G
Prl8a4
prolactin family 8, subfamily A, member 4
increases expression
EXP
bexarotene results in increased expression of PRL8A4 mRNA
CTD
PMID:16648578
NCBI chr17:37,429,960...37,436,053
Ensembl chr17:37,429,960...37,436,053
G
Prlhr
prolactin releasing hormone receptor
increases expression
EXP
bexarotene results in increased expression of PRLHR mRNA
CTD
PMID:16648578
NCBI chr 1:259,606,704...259,608,391
Ensembl chr 1:259,606,704...259,608,391
G
Prlr
prolactin receptor
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of PRLR mRNA
CTD
PMID:17630414
NCBI chr 2:59,134,147...59,324,719
Ensembl chr 2:59,134,588...59,324,718
G
Prnp
prion protein
decreases expression
EXP
bexarotene results in decreased expression of PRNP mRNA
CTD
PMID:16648578
NCBI chr 3:119,186,073...119,201,513
Ensembl chr 3:119,177,485...119,203,937
G
Prom1
prominin 1
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of PROM1 mRNA
CTD
PMID:17630414
NCBI chr14:66,989,545...67,094,534
Ensembl chr14:66,990,160...67,094,527
G
Prr15
proline rich 15
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of PRR15 mRNA
CTD
PMID:17630414
NCBI chr 4:83,432,002...83,435,582
Ensembl chr 4:83,431,758...83,437,436
G
Psap
prosaposin
increases expression
EXP
bexarotene results in increased expression of PSAP mRNA
CTD
PMID:16648578
NCBI chr20:28,214,229...28,240,501
Ensembl chr20:28,214,271...28,240,498
G
Psmc2
proteasome 26S subunit, ATPase 2
increases expression
EXP
bexarotene results in increased expression of PSMC2 mRNA
CTD
PMID:16648578
NCBI chr 4:13,255,851...13,270,102
Ensembl chr 4:13,255,856...13,270,185
G
Psmd4
proteasome 26S subunit ubiquitin receptor, non-ATPase 4
increases expression
EXP
bexarotene results in increased expression of PSMD4 mRNA
CTD
PMID:16648578
NCBI chr 2:182,598,934...182,608,250
Ensembl chr 2:182,598,934...182,608,194
G
Pspn
persephin
increases expression
EXP
bexarotene results in increased expression of PSPN mRNA
CTD
PMID:16648578
NCBI chr 9:1,841,105...1,841,663
Ensembl chr 9:1,840,896...1,854,327
G
Ptger3
prostaglandin E receptor 3
decreases expression
ISO
bexarotene results in decreased expression of PTGER3 mRNA
CTD
PMID:17849452
NCBI chr 2:246,606,131...246,750,970
Ensembl chr 2:246,606,183...246,684,434
G
Ptger4
prostaglandin E receptor 4
decreases expression
ISO
bexarotene results in decreased expression of PTGER4 mRNA
CTD
PMID:17849452
NCBI chr 2:54,330,563...54,347,451
Ensembl chr 2:54,335,424...54,346,670
G
Ptms
parathymosin
increases expression
EXP
bexarotene results in increased expression of PTMS mRNA
CTD
PMID:16648578
NCBI chr 4:157,722,384...157,726,575
Ensembl chr 4:157,722,386...157,727,009
G
Ptprc
protein tyrosine phosphatase, receptor type, C
increases expression
EXP
bexarotene results in increased expression of PTPRC mRNA
CTD
PMID:16648578
NCBI chr13:49,596,193...49,708,283
Ensembl chr13:49,596,193...49,708,692
G
Qpct
glutaminyl-peptide cyclotransferase
increases expression
EXP
bexarotene results in increased expression of QPCT mRNA
CTD
PMID:16648578
NCBI chr 6:15,964,656...15,996,925
Ensembl chr 6:15,964,657...15,996,711
G
Rab11b
RAB11B, member RAS oncogene family
increases expression
EXP
bexarotene results in increased expression of RAB11B mRNA
CTD
PMID:16648578
NCBI chr 7:14,521,448...14,534,589
Ensembl chr 7:14,521,368...14,534,593
G
Rab7a
RAB7A, member RAS oncogene family
increases expression
EXP
bexarotene results in increased expression of RAB7 mRNA
CTD
PMID:16648578
NCBI chr 4:120,461,966...120,510,756
Ensembl chr 4:120,461,963...120,506,889
G
Rabep2
rabaptin, RAB GTPase binding effector protein 2
increases expression
EXP
bexarotene results in increased expression of RABEP2 mRNA
CTD
PMID:16648578
NCBI chr 1:181,010,305...181,026,651
Ensembl chr 1:181,010,305...181,026,648
G
Rarb
retinoic acid receptor, beta
increases expression
ISO
bexarotene results in increased expression of RARB mRNA
CTD
PMID:17178900
NCBI chr15:8,700,533...9,051,288
Ensembl chr15:8,406,492...9,051,288
G
Rasl11a
RAS-like family 11 member A
increases expression
EXP
bexarotene results in increased expression of RASL11A mRNA
CTD
PMID:16648578
NCBI chr12:8,258,148...8,262,576
Ensembl chr12:8,258,159...8,262,576
G
Rassf1
Ras association domain family member 1
decreases expression
ISO
bexarotene results in decreased expression of RASSF1 mRNA
CTD
PMID:17849452
NCBI chr 8:108,225,023...108,236,164
Ensembl chr 8:108,225,023...108,236,164
G
Rb1
RB transcriptional corepressor 1
decreases phosphorylation
ISO
bexarotene results in decreased phosphorylation of RB1 protein
CTD
PMID:16273314
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
G
Rdh16
retinol dehydrogenase 16
increases expression
EXP
bexarotene results in increased expression of RDH2 mRNA
CTD
PMID:16648578
NCBI chr 7:63,616,724...63,624,120
Ensembl chr 7:63,597,536...63,624,124
G
Renbp
renin binding protein
increases expression
EXP
bexarotene results in increased expression of RENBP mRNA
CTD
PMID:16648578
NCBI chr X:151,661,463...151,670,538
Ensembl chr X:151,661,458...151,670,516
G
Rest
RE1-silencing transcription factor
increases expression
EXP
bexarotene results in increased expression of REST mRNA
CTD
PMID:16648578
NCBI chr14:30,859,109...30,879,828
Ensembl chr14:30,862,553...30,894,354
G
Rgn
regucalcin
decreases expression
EXP
bexarotene results in decreased expression of RGN mRNA
CTD
PMID:16648578
NCBI chr X:1,619,030...1,634,456
Ensembl chr X:1,619,032...1,634,450
G
Rida
reactive intermediate imine deaminase A homolog
decreases expression
EXP
bexarotene results in decreased expression of RIDA mRNA
CTD
PMID:16648578
NCBI chr 7:65,691,429...65,705,257
Ensembl chr 7:65,691,435...65,705,716
G
Rnase1
ribonuclease A family member 1, pancreatic
increases expression
EXP
Bexarotene results in increased expression of RNASE1 mRNA
CTD
PMID:16648578
NCBI chr15:24,361,924...24,363,658
Ensembl chr15:24,361,927...24,363,624
G
Rpl18a
ribosomal protein L18A
increases expression
EXP
bexarotene results in increased expression of RPL18A mRNA
CTD
PMID:16648578
NCBI chr16:18,542,572...18,544,578
Ensembl chr16:18,542,566...18,545,546
G
Rpl22
ribosomal protein L22
increases expression
EXP
bexarotene results in increased expression of RPL22 mRNA
CTD
PMID:16648578
NCBI chr 5:162,835,251...162,841,977
Ensembl chr 5:162,833,740...162,843,368
G
Rpl7a
ribosomal protein L7A
increases expression
EXP
bexarotene results in increased expression of RPL7A mRNA
CTD
PMID:16648578
NCBI chr 3:10,239,026...10,241,703
Ensembl chr 3:10,239,001...10,241,716
G
Rps2
ribosomal protein S2
increases expression
EXP
bexarotene results in increased expression of RPS2 mRNA
CTD
PMID:16648578
NCBI chr10:13,747,316...13,749,165
Ensembl chr10:13,747,301...13,749,163
G
Rpsa
ribosomal protein SA
increases expression
EXP
bexarotene results in increased expression of RPSA mRNA
CTD
PMID:16648578
NCBI chr 8:119,851,225...119,855,103
Ensembl chr 8:119,851,225...119,855,247
G
RT1-Ba
RT1 class II, locus Ba
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of RT1-BA mRNA
CTD
PMID:17630414
NCBI chr20:4,575,134...4,579,727
Ensembl chr20:4,575,134...4,579,744
G
RT1-Cl
RT1 class Ib, locus Cl
increases expression
EXP
bexarotene results in increased expression of RT1-CL mRNA
CTD
PMID:16648578
G
RT1-Da
RT1 class II, locus Da
multiple interactions increases expression
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of RT1-DA mRNA bexarotene results in increased expression of RT1-DA mRNA
CTD
PMID:16648578 PMID:17630414
NCBI chr20:4,513,464...4,518,457
Ensembl chr20:4,512,911...4,518,455
G
RT1-Db1
RT1 class II, locus Db1
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of RT1-DB1 mRNA
CTD
PMID:17630414
NCBI chr20:4,548,664...4,558,237
Ensembl chr20:4,548,666...4,558,258
G
Rtn4
reticulon 4
increases expression
EXP
bexarotene results in increased expression of RTN4 mRNA
CTD
PMID:17630414
NCBI chr14:103,450,074...103,497,687
Ensembl chr14:103,449,930...103,497,686
G
Rxra
retinoid X receptor alpha
affects binding multiple interactions
ISO
Bexarotene binds to RXRA protein Bexarotene binds to and results in increased activity of RXRA protein; RXRA promotes the reaction [Bexarotene results in increased expression of APOA2 mRNA]; RXRA protein affects the reaction [Bexarotene results in increased expression of CYP2B6 mRNA]; RXRA protein affects the reaction [Bexarotene results in increased expression of HSD11B2 mRNA]; RXRA protein affects the reaction [Bexarotene results in increased expression of HSD11B2 protein]
CTD
PMID:8668150 PMID:21218783 PMID:23843199 PMID:31312845 PMID:31566444 PMID:31927052 More...
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
G
Rxrb
retinoid X receptor beta
affects binding
ISO
bexarotene binds to RXRB protein
CTD
PMID:23843199
NCBI chr20:4,816,813...4,823,267
Ensembl chr20:4,816,815...4,828,773
G
Rxrg
retinoid X receptor gamma
affects binding decreases expression
ISO
bexarotene binds to RXRG protein bexarotene results in decreased expression of RXRG mRNA
CTD
PMID:17849452 PMID:23843199
NCBI chr13:79,743,430...79,785,173
Ensembl chr13:79,743,563...79,785,167
G
S100a10
S100 calcium binding protein A10
decreases expression
EXP
bexarotene results in decreased expression of S100A10 mRNA
CTD
PMID:16648578
NCBI chr 2:179,221,012...179,229,659
Ensembl chr 2:179,220,887...179,229,661
G
S100a9
S100 calcium binding protein A9
increases expression
ISO EXP
bexarotene results in increased expression of S100A9 mRNA
CTD
PMID:16648578 PMID:17178900
NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230
G
S100b
S100 calcium binding protein B
decreases expression
EXP
bexarotene results in decreased expression of S100B mRNA
CTD
PMID:16648578
NCBI chr20:12,372,866...12,381,619
Ensembl chr20:12,372,881...12,394,743
G
Scd
stearoyl-CoA desaturase
increases expression multiple interactions
ISO EXP
bexarotene results in increased expression of SCD1 mRNA [Bexarotene co-treated with GW 3965] results in increased expression of SCD mRNA; [Bexarotene co-treated with T0901317] results in increased expression of SCD mRNA [Tamoxifen co-treated with bexarotene] results in increased expression of SCD1 mRNA Bexarotene results in increased expression of SCD mRNA
CTD
PMID:17178900 PMID:17630414 PMID:23292798 PMID:32123961
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
G
Scd2
stearoyl-Coenzyme A desaturase 2
increases expression
EXP
bexarotene results in increased expression of SCD2 mRNA
CTD
PMID:16648578 PMID:17630414
NCBI chr 1:243,169,171...243,182,231
Ensembl chr 1:243,169,236...243,182,232
G
Scp2
sterol carrier protein 2
decreases expression
EXP
bexarotene results in decreased expression of SCP2 mRNA
CTD
PMID:16648578
NCBI chr 5:122,806,949...122,881,259
Ensembl chr 5:122,776,549...122,881,287
G
Sdc2
syndecan 2
decreases expression
EXP
bexarotene results in decreased expression of SDC2 mRNA
CTD
PMID:16648578
NCBI chr 7:64,127,185...64,239,885
Ensembl chr 7:64,127,110...64,241,081
G
Serpina1
serpin family A member 1
decreases expression
EXP
bexarotene results in decreased expression of SERPINA1 mRNA
CTD
PMID:16648578
NCBI chr 6:122,866,314...122,888,339
Ensembl chr 6:122,866,312...122,888,339
G
Serpina3n
serine (or cysteine) peptidase inhibitor, clade A, member 3N
decreases expression
EXP
bexarotene results in decreased expression of SERPINA3N mRNA
CTD
PMID:16648578
NCBI chr 6:123,323,632...123,331,166
Ensembl chr 6:123,323,629...123,332,433
G
Serpind1
serpin family D member 1
decreases expression
EXP
bexarotene results in decreased expression of SERPIND1 mRNA
CTD
PMID:16648578
NCBI chr11:83,664,517...83,675,593
Ensembl chr11:83,664,518...83,675,519
G
Serpinh1
serpin family H member 1
increases expression
EXP
bexarotene results in increased expression of SERPINH1 mRNA
CTD
PMID:17630414
NCBI chr 1:153,643,500...153,650,853
Ensembl chr 1:153,643,510...153,650,801
G
Sfpq
splicing factor proline and glutamine rich
decreases expression
EXP
bexarotene results in decreased expression of SFPQ mRNA
CTD
PMID:16648578
NCBI chr 5:139,338,034...139,353,476
Ensembl chr 5:139,338,075...139,353,472
G
Shh
sonic hedgehog signaling molecule
increases expression
ISO
bexarotene results in increased expression of SHH mRNA
CTD
PMID:26096596
NCBI chr 4:6,954,017...6,963,170
Ensembl chr 4:6,954,017...6,963,170
G
Siah2
siah E3 ubiquitin protein ligase 2
decreases expression
ISO
bexarotene results in decreased expression of SIAH2 mRNA
CTD
PMID:17178900
NCBI chr 2:142,913,924...142,931,752
Ensembl chr 2:142,914,003...142,931,950
G
Slc1a3
solute carrier family 1 member 3
decreases expression
EXP
bexarotene results in decreased expression of SLC1A3 mRNA
CTD
PMID:16648578
NCBI chr 2:57,755,495...57,830,605
Ensembl chr 2:57,755,497...57,830,605
G
Slc27a1
solute carrier family 27 member 1
increases expression multiple interactions
EXP ISO
bexarotene results in increased expression of SLC27A1 mRNA [[Dexamethasone co-treated with INS protein co-treated with 1-Methyl-3-isobutylxanthine] co-treated with bexarotene] results in increased expression of SLC27A1 mRNA
CTD
PMID:10777552
NCBI chr16:18,278,984...18,300,173
Ensembl chr16:18,278,984...18,296,063
G
Slc27a2
solute carrier family 27 member 2
decreases expression
EXP
bexarotene results in decreased expression of SLC27A2 mRNA
CTD
PMID:16648578
NCBI chr 3:113,804,728...113,842,208
Ensembl chr 3:113,804,728...113,842,208
G
Slc2a2
solute carrier family 2 member 2
increases expression
EXP
bexarotene results in increased expression of SLC2A2 mRNA
CTD
PMID:16648578
NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933
G
Slc2a4
solute carrier family 2 member 4
multiple interactions
ISO
[bexarotene co-treated with rosiglitazone] results in increased expression of SLC2A4 mRNA
CTD
PMID:10548525
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
G
Slc35b1
solute carrier family 35, member B1
increases expression
EXP
bexarotene results in increased expression of SLC35B1 mRNA
CTD
PMID:16648578
NCBI chr10:80,327,921...80,335,279
Ensembl chr10:80,327,945...80,335,274
G
Slc6a6
solute carrier family 6 member 6
increases expression
EXP
bexarotene results in increased expression of SLC6A6 mRNA
CTD
PMID:16648578
NCBI chr 4:124,195,186...124,268,880
Ensembl chr 4:124,195,218...124,268,875
G
Slc7a1
solute carrier family 7 member 1
decreases expression
ISO
bexarotene results in decreased expression of SLC7A1 mRNA
CTD
PMID:17178900
NCBI chr12:6,628,214...6,703,849
Ensembl chr12:6,628,007...6,703,849
G
Slc7a5
solute carrier family 7 member 5
decreases expression
ISO
bexarotene results in decreased expression of SLC7A5 mRNA
CTD
PMID:17178900
NCBI chr19:49,935,220...49,963,823
Ensembl chr19:49,935,220...49,963,823
G
Smad5
SMAD family member 5
increases expression
ISO
bexarotene results in increased expression of SMAD5 mRNA
CTD
PMID:17178900
NCBI chr17:7,862,332...7,891,678
Ensembl chr17:7,864,720...7,891,634
G
Sncg
synuclein, gamma
decreases expression
EXP
bexarotene results in decreased expression of SNCG mRNA
CTD
PMID:16648578
NCBI chr16:9,700,513...9,705,751
Ensembl chr16:9,700,514...9,705,368
G
Snd1
staphylococcal nuclease and tudor domain containing 1
increases expression
EXP
bexarotene results in increased expression of SND1 mRNA
CTD
PMID:16648578
NCBI chr 4:57,095,205...57,494,501
Ensembl chr 4:57,095,208...57,530,843
G
Snn
stannin
decreases expression
EXP
bexarotene results in decreased expression of SNN mRNA
CTD
PMID:16648578
NCBI chr10:4,572,933...4,581,606
Ensembl chr10:4,572,376...4,584,021
G
Sord
sorbitol dehydrogenase
decreases expression
EXP
bexarotene results in decreased expression of SORD mRNA
CTD
PMID:16648578
NCBI chr 3:109,184,697...109,216,133
Ensembl chr 3:109,184,676...109,216,133
G
Sorl1
sortilin related receptor 1
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of SORL1 mRNA
CTD
PMID:17630414
NCBI chr 8:42,341,704...42,504,435
Ensembl chr 8:42,341,704...42,504,513
G
Sp7
Sp7 transcription factor
decreases expression multiple interactions
ISO
bexarotene results in decreased expression of SP7 mRNA bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]
CTD
PMID:25932594
NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847
G
Sparc
secreted protein acidic and cysteine rich
increases expression
ISO
bexarotene results in increased expression of SPARC mRNA
CTD
PMID:17178900
NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396
G
Spink1
serine peptidase inhibitor, Kazal type 1
multiple interactions increases expression
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of SPINK1 mRNA bexarotene results in increased expression of SPINK1 mRNA
CTD
PMID:16648578 PMID:17630414
NCBI chr18:35,870,723...35,882,693
Ensembl chr18:35,824,550...35,882,642
G
Spp1
secreted phosphoprotein 1
decreases expression
EXP
bexarotene results in decreased expression of SPP1 mRNA
CTD
PMID:16648578
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
G
Spp2
secreted phosphoprotein 2
decreases expression
EXP
bexarotene results in decreased expression of SPP2 mRNA
CTD
PMID:16648578
NCBI chr 9:89,006,858...89,026,676
Ensembl chr 9:89,007,175...89,026,688
G
Spt1
salivary protein 1
decreases expression
EXP
bexarotene results in decreased expression of SPT1 mRNA
CTD
PMID:16648578
NCBI chr 7:134,914,177...134,924,215
Ensembl chr 7:134,914,177...134,924,157
G
Sqstm1
sequestosome 1
increases expression
EXP
bexarotene results in increased expression of SQSTM1 mRNA
CTD
PMID:16648578
NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
G
Srd5a1
steroid 5 alpha-reductase 1
decreases expression
EXP
bexarotene results in decreased expression of SRD5A1 mRNA
CTD
PMID:16648578
NCBI chr 1:33,686,069...33,720,468
Ensembl chr 1:33,686,391...33,720,461
G
Srebf1
sterol regulatory element binding transcription factor 1
increases expression multiple interactions
EXP ISO
bexarotene results in increased expression of SREBF1 mRNA Bexarotene results in increased expression of SREBF1 mRNA [Bexarotene co-treated with GW 3965] results in increased expression of SREBF1 mRNA; [Bexarotene co-treated with paxilline] results in increased expression of SREBF1 mRNA; [Bexarotene co-treated with T0901317] results in increased expression of SREBF1 mRNA; Bexarotene promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SREBF1 mRNA]
CTD
PMID:23292798 PMID:25932594 PMID:32123961
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
G
Srsf2
serine and arginine rich splicing factor 2
decreases expression
ISO
bexarotene results in decreased expression of SRSF2 mRNA
CTD
PMID:17178900
NCBI chr10:102,052,158...102,055,365
Ensembl chr10:102,052,314...102,055,338
G
Sult1a1
sulfotransferase family 1A member 1
decreases expression
EXP
bexarotene results in decreased expression of SULT1A1 mRNA
CTD
PMID:16648578
NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562
G
Sult1b1
sulfotransferase family 1B member 1
decreases expression
EXP
bexarotene results in decreased expression of SULT1B1 mRNA
CTD
PMID:16648578
NCBI chr14:20,492,763...20,505,491
Ensembl chr14:20,492,708...20,505,483
G
Sult2a1
sulfotransferase family 2A member 1
decreases expression
EXP
bexarotene results in decreased expression of SULT2A1 mRNA
CTD
PMID:16648578
NCBI chr 1:75,451,178...75,508,142
Ensembl chr 1:74,911,100...75,508,134
G
Tacr2
tachykinin receptor 2
increases expression
EXP
bexarotene results in increased expression of TACR2 mRNA
CTD
PMID:16648578
NCBI chr20:30,208,907...30,223,446
Ensembl chr20:30,208,907...30,223,446
G
Tecr
trans-2,3-enoyl-CoA reductase
increases expression
EXP
bexarotene results in increased expression of TECR mRNA
CTD
PMID:16648578
NCBI chr19:24,526,705...24,568,168
Ensembl chr19:24,541,615...24,568,168
G
Tex49
testis expressed 49
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of TEX49 mRNA
CTD
PMID:17630414
NCBI chr 7:129,720,950...129,742,485
Ensembl chr 7:129,720,950...129,742,485
G
Tf
transferrin
increases expression
EXP
bexarotene results in increased expression of TF mRNA
CTD
PMID:16648578
NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511
G
Tg
thyroglobulin
increases expression
EXP
bexarotene results in increased expression of TG mRNA
CTD
PMID:16648578
NCBI chr 7:98,418,293...98,603,210
Ensembl chr 7:98,418,293...98,603,210
G
Tgfb3
transforming growth factor, beta 3
increases expression
EXP
bexarotene results in increased expression of TGFB3 mRNA
CTD
PMID:16648578
NCBI chr 6:105,704,058...105,726,661
Ensembl chr 6:105,704,236...105,726,564
G
Tgm1
transglutaminase 1
decreases expression
ISO
bexarotene results in decreased expression of TGM1 mRNA
CTD
PMID:8853895
NCBI chr15:29,191,039...29,206,000
Ensembl chr15:29,191,041...29,204,523
G
Tgm2
transglutaminase 2
increases expression multiple interactions
ISO
bexarotene results in increased expression of TGM2 mRNA diazepinylbenzoic acid inhibits the reaction [bexarotene results in increased expression of TGM2 mRNA]
CTD
PMID:17178900 PMID:21622945 PMID:25932594
NCBI chr 3:146,772,684...146,801,924
Ensembl chr 3:146,772,687...146,801,981
G
Thra
thyroid hormone receptor alpha
multiple interactions
ISO
bexarotene binds to and results in decreased activity of THRA protein
CTD
PMID:25752796
NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936
G
Tm4sf1
transmembrane 4 L six family member 1
increases expression
ISO
bexarotene results in increased expression of TM4SF1 mRNA
CTD
PMID:17178900
NCBI chr 2:141,456,950...141,466,146
Ensembl chr 2:141,453,310...141,466,146
G
Tmed2
transmembrane p24 trafficking protein 2
increases expression
EXP
bexarotene results in increased expression of TMED2 mRNA
CTD
PMID:16648578
NCBI chr12:32,052,542...32,061,596
Ensembl chr12:32,052,543...32,071,903
G
Tnfrsf1a
TNF receptor superfamily member 1A
increases expression
EXP
bexarotene results in increased expression of TNFRSF1A mRNA
CTD
PMID:16648578
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
G
Tns1
tensin 1
increases expression
EXP
bexarotene results in increased expression of TNS1 mRNA
CTD
PMID:16648578
NCBI chr 9:75,491,886...75,702,853
Ensembl chr 9:75,495,814...75,703,225
G
Tp53
tumor protein p53
multiple interactions
ISO
bexarotene results in increased phosphorylation of and results in increased activity of TP53 protein
CTD
PMID:19067706
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
G
Tp73
tumor protein p73
increases expression
ISO
bexarotene results in increased expression of TP73 protein
CTD
PMID:19067706
NCBI chr 5:164,621,377...164,703,958
Ensembl chr 5:164,621,377...164,681,128
G
Tpm1
tropomyosin 1
increases expression
EXP
bexarotene results in increased expression of TPM1 mRNA
CTD
PMID:16648578
NCBI chr 8:67,635,479...67,662,330
Ensembl chr 8:67,635,479...67,662,802
G
Tpm3
tropomyosin 3
increases expression
EXP
bexarotene results in increased expression of TPM3 mRNA
CTD
PMID:16648578
NCBI chr 2:175,517,198...175,545,014
Ensembl chr 2:175,517,226...175,545,013
G
Tpm4
tropomyosin 4
increases expression
EXP
bexarotene results in increased expression of TPM4 mRNA
CTD
PMID:16648578
NCBI chr16:17,684,415...17,698,456
Ensembl chr16:17,683,195...17,705,984
G
Tsc22d3
TSC22 domain family, member 3
increases expression
ISO
bexarotene results in increased expression of TSC22D3 mRNA
CTD
PMID:17178900
NCBI chr X:104,217,898...104,277,935
Ensembl chr X:104,217,925...104,276,861
G
Ttr
transthyretin
decreases expression
EXP
bexarotene results in decreased expression of TTR mRNA
CTD
PMID:16648578
NCBI chr18:11,941,791...11,951,008
Ensembl chr18:11,943,789...11,951,008
G
Tuba1a
tubulin, alpha 1A
increases expression
EXP
bexarotene results in increased expression of TUBA1A mRNA
CTD
PMID:16648578
NCBI chr 7:130,113,214...130,116,880
Ensembl chr 7:130,081,032...130,196,186
G
Uap1
UDP-N-acetylglucosamine pyrophosphorylase 1
decreases expression
ISO
bexarotene results in decreased expression of UAP1 mRNA
CTD
PMID:17178900
NCBI chr13:82,342,946...82,377,558
Ensembl chr13:82,342,946...82,377,469
G
Ucp2
uncoupling protein 2
multiple interactions
ISO
bexarotene promotes the reaction [rosiglitazone results in increased expression of UCP2 mRNA]
CTD
PMID:10548525
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
G
Ugt2b
UDP glycosyltransferase 2 family, polypeptide B
decreases expression
EXP
bexarotene results in decreased expression of UGT2B mRNA
CTD
PMID:16648578
NCBI chr14:20,630,572...20,665,062
Ensembl chr14:20,630,250...20,651,776
G
Vamp8
vesicle-associated membrane protein 8
increases expression
ISO
bexarotene results in increased expression of VAMP8 mRNA
CTD
PMID:17178900
NCBI chr 4:104,442,383...104,452,884
Ensembl chr 4:104,442,393...104,452,897
G
Vegfa
vascular endothelial growth factor A
increases expression
EXP
bexarotene results in increased expression of VEGFA mRNA
CTD
PMID:16648578
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
G
Xbp1
X-box binding protein 1
decreases expression
ISO
bexarotene results in decreased expression of XBP1 mRNA
CTD
PMID:17178900
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
G
Ywhah
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta
decreases expression
EXP
bexarotene results in decreased expression of YWHAH mRNA
CTD
PMID:16648578
NCBI chr14:77,696,332...77,705,715
Ensembl chr14:77,696,333...77,705,741
G
Zbtb16
zinc finger and BTB domain containing 16
increases expression
EXP
bexarotene results in increased expression of ZBTB16 mRNA
CTD
PMID:23292798
NCBI chr 8:48,989,376...49,177,011
Ensembl chr 8:48,994,566...49,177,011
G
Zp3
zona pellucida glycoprotein 3
increases expression
EXP
bexarotene results in increased expression of ZP3 mRNA
CTD
PMID:16648578
NCBI chr12:20,690,547...20,697,513
Ensembl chr12:20,690,547...20,697,513
Term paths to the root one shortest all shortest one longest all longest one shortest and longest all